


Invesco UK 2 Investment Series

Annual Report Including Long Form Financial Statements

Issued September 2020For the year 1 April 2019 to 31 March 2020



Contents	
02 06	Invesco UK 2 Investment Series (the "Company") Report of the Authorised Corporate Director (the "Manager")* Notes applicable to the financial statements of all Funds
16 17 18 22 26 35	Invesco Income Fund (UK)** Strategy, review and outlook* Comparative tables Portfolio statement* Financial statements Distribution tables
37 38 39 42 46 54	Invesco UK Enhanced Index Fund (UK) Strategy, review and outlook* Comparative tables Portfolio statement* Financial statements Distribution tables
55 56 57 61 64 73	Invesco UK Strategic Income Fund (UK) Strategy, review and outlook* Comparative tables Portfolio statement* Financial statements Distribution tables
75 75 75 75	Regulatory Statements Statement of the Manager's responsibilities Statement of the Depositary's responsibilities Depositary's Report to Shareholders
76	Independent auditors' report to the Shareholders of Invesco UK 2 Investment Series
78	General Information*

 ^{*} These collectively comprise the Authorised Corporate Director's Report.
 ** Effective 30 July 2020 the Invesco Income Fund (UK) changed its name to Invesco UK Equity Income Fund (UK).

Report of the Authorised Corporate Director (the "Manager")

The Company

The Invesco UK 2 Investment Series is an investment company with variable capital ("ICVC"), incorporated in England and Wales on 11 April 2003.

The Company is a "UCITS Scheme" and an "Umbrella Company" (under the OEIC Regulations) and therefore new Funds may be formed by the Manager, subject to regulatory approval. Any changes to Funds or share classes will be included in an updated Prospectus.

The Company is a Financial Conduct Authority (FCA) authorised scheme complying with the FCA's Collective Investment Schemes sourcebook.

Terms used in this report shall have the same meaning as defined in the Prospectus.

At 31 March 2020, the Company consisted of three Funds:

Invesco Income Fund (UK) Invesco UK Enhanced Index Fund (UK) Invesco UK Strategic Income Fund (UK)

Effective 30 July 2020 the Invesco Income Fund (UK) changed its name to Invesco UK Equity Income Fund (UK).

Effective 31 July 2020 the Invesco UK Strategic Income Fund (UK) merged into the Invesco UK Equity Income Fund (UK).

Accounting Periods

Annual accounting date 31 March
Interim accounting date 30 September
Distribution payable on 31 May
Interim distribution payable on 30 November

Should expenses and taxation exceed revenue in a distribution period for a share class, no distribution will be payable for that class.

Securities Financing Transactions Regulation (Unaudited)

This Regulation requires the Manager to provide investors with information on the use of securities financing transactions (SFTs) and total return swaps (TRS) by the Company in all interim and annual reports for the Company.

During the year from 1 April 2019 to 31 March 2020, none of the Funds entered into any SFTs and/or TRS. Should this change in the future, the interim and annual reports for the Company will disclose all required information on the use of SFTs and TRS by the Company.

Please refer to the Prospectus for further details on SFTs and TRS.

Fund Events

On the 7 August 2019 there was an update to the Prospectus for the various ICVC funds in light of the FCA's Asset Management Study. As part of this update, various changes were implemented regarding investment objectives, investment policies, investment strategies and benchmark disclosures, all for clarification purposes only. There has been no changes to the way the Funds are managed as a result of these changes. The updated prospectus is available at www.invesco.co.uk.

Fund Events - Directors Report

The net asset value in pence per share at the balance sheet date has been shown in the table below.

	Net Asset Value 31.3.20 Accounting NAV Per Financial Statement (pence per share)	Net Asset Value 31.3.20 Dealing NAV (pence per share)
Invesco Income Fund (UK) Z Accumulation shares* Invesco UK Enhanced	217.06	208.30
Index Fund (UK) Z Accumulation shares* Invesco UK Strategic	195.29	195.30
Income Fund (UK) Z Accumulation shares*	227.55	218.10

* The prices stated are that of the primary share class. The movements are reflective of the movements for all share classes within the Fund.

On 31 March 2020 we announced our intention to dispose of the unquoted assets within the Invesco Income Fund (UK) and Invesco UK Strategic Income Fund (UK) as a portfolio in order to redeploy capital raised to publicly quoted assets. In order to ensure we were protecting the interests of all investors in the Funds in an equitable way in accordance with the Collective Investment Schemes Sourcebook of the FCA Handbook, and to mitigate any potential conflicts of interest, in line with internal pricing policies, the independent Unquoted Pricing Committee reviewed the value of the unquoted portfolio and determined a market clearing price at 31 March 2020 to reflect the market conditions at that time. A 60% mark-down was as a result made to the values of the unquoted stocks, in accordance with policies of the independent Unquoted Pricing Committee. For accounting purposes at the year end of 31 March 2020 the unquoted investments continued however to be valued on an individual basis in accordance with UK Generally Accepted Accounting Practice using the methodology outlined in Note 1, Accounting Policies.

Remuneration Policy (Unaudited)

On 18 March 2016, Invesco Fund Managers Limited (the "Manager") adopted a remuneration policy consistent with the principles outlined in the European Securities and Markets Authority (ESMA) Guidelines, on sound remuneration policies under the UCITS Directive (the "Remuneration Policy").

The policy was revised in 2019, to include specificities for some Invesco EU regulated Management Companies. The Manager was not impacted by the changes.

The purpose of the Remuneration Policy is to ensure the remuneration of the staff of the Manager is consistent with and promotes sound and effective risk management, does not encourage risk-taking which is inconsistent with the risk profiles, rules or instruments of incorporation of the Manager and of the UCITS it manages and does not impair the Manager's compliance with its duty to act in the best interests of the UCITS it manages. The Manager's summary Remuneration Policy is available from the corporate policies section of our website (www.invesco.co.uk). Paper copies of the full Remuneration Policy can be obtained for free from

Report of the Authorised Corporate Director (the "Manager")

Remuneration Policy (Unaudited) continued the registered office of the Manager, Invesco Fund Managers Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, UK upon request.

The Remuneration Policy is reviewed annually by the Compliance, Human Resources and Risk Management functions, who recommend any adjustments to ensure continued alignment of the policy with sound risk management. The board of directors of the Manager are responsible for the oversight of remuneration and for ensuring adherence to this policy through the Human Resources function.

The Internal Audit function conducts regular testing of administration of the Remuneration Policy to assess its ongoing compliance with the Invesco Group's remuneration policies and procedures.

The Manager does not employ any direct staff. The aggregate total remuneration of Invesco staff involved in UCITS related activities of the Manager in respect of performance year (1 January 2019 to 31 December 2019) is £80.14m of which £47.43m is fixed remuneration and £32.71m is variable remuneration. The number of beneficiaries is 379.

The Manager has identified individuals considered to have a material impact on the risk profile of the Manager or the UCITS it manages ("Identified Staff"), who include board members of the Manager, senior management, heads of control functions, other risk takers and any employees receiving total remuneration that takes them into the same remuneration bracket as senior management and risk takers. Identified Staff of the Manager are employed by Invesco.

The aggregate total remuneration paid to the Identified Staff of the Manager for UCITS related activities for the performance year (1 January 2019 to 31 December 2019) is £11.79m of which £2.34m is paid to Senior Management and £9.45m is paid to other Identified Staff.

Share Classes Available

Invesco Income Fund (UK)

Accumulation shares
Accumulation shares (No Trail)
Z Accumulation shares
Y Accumulation shares
Income shares
Income shares (No Trail)
Z Income shares

Y Income shares

Invesco UK Enhanced Index Fund (UK)

Accumulation shares (No Trail)
Z Accumulation shares
Y Accumulation shares
Income shares (No Trail)
Z Income shares
Y Income shares

Invesco UK Strategic Income Fund (UK)

Accumulation shares
Accumulation shares (No Trail)
Z Accumulation shares
Y Accumulation shares
Income shares
Income shares (No Trail)
Z Income shares
Y Income shares

The prices of shares will appear on our website (www.invesco.co.uk). This is the primary method of price publication. The prices of shares may also be obtained by calling 0800 085 8677 during the Manager's normal business hours.

Brexit

The UK left the EU on 31 January 2020, an event commonly referred to as Brexit. At the date of this report, discussions remain ongoing as to the precise nature of the future relationship between the UK and EU27. The Authorised Corporate Director does not believe that Brexit will present significant issues that cannot be mitigated given that no Fund is passported into Europe, Shareholders are predominantly UKbased and core counterparties of and service providers to the Company have contingency arrangements available as necessary to ensure that activities can continue with minimal disruption. In addition, on 30 January 2019, EU27 national regulators and the UK's Financial Conduct Authority agreed Memoranda of Understanding in the event of a no-deal Brexit scenario on various matters related to the conduct of financial services and trading activities.

The Company's Manager, Invesco Fund Managers Limited "IFML", is part of a global group and has been committed for many years to meeting clients' needs across Europe in both EU and non-EU countries. The change in the UK's status from an EU to a non-EU country will not change the group's focus or commitment to serve its clients across Europe. IFML is monitoring developments closely, through a Brexit Steering Committee, and will take advantage of the Memoranda of Understanding to ensure that the impact on clients and the Company is minimal.

Managing the risks presented by the outbreak of Coronavirus

The spread of a new coronavirus (COVID-19) disease has caused significant volatility within the global economy and financial markets. There has been no material impact to the Funds of the Company as a result of COVID-19 during the financial period ended 31 March 2020.

The directors of Invesco Fund Managers Limited are actively monitoring the situation and, with the support of the investment manager, continue to manage the Fund's assets within its investment and risk parameters that have been established. The Directors will continue to review the situation in order to navigate through this period of heightened uncertainty.

Report of the Authorised Corporate Director (the "Manager")

Risk Profile

Shareholders should be aware of the risks inherent in investing in securities and other financial instruments. Financial markets can be vulnerable to unpredictable price movements and are affected by a number of factors, both political and economic.

The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested. Over time, inflation may erode the value of investments.

As one of the key objectives of the Invesco Income Fund (UK) and Invesco UK Strategic Income Fund (UK) is to provide income, the ongoing charge is taken from capital rather than income. This can erode capital and reduce the potential for capital growth.

The Invesco Income Fund (UK) may invest in private and unlisted equities, the Invesco UK Strategic Income Fund (UK) up to its merger date 31 July 2020 had the ability to invest in private and unlisted equities which may involve additional risks such as lack of liquidity and concentrated ownership. These investments may result in greater fluctuations of the value of the Funds. The Manager, will ensure that any investments in private and unlisted equities do not materially alter the overall risk profile of the Funds.

The Invesco Income Fund (UK) invests in smaller companies, the Invesco UK Strategic Income Fund (UK) up to its merger date of 31 July 2020 had the ability to invest in smaller companies which may result in a higher level of risk than a fund that invests in larger companies. Securities of smaller companies may be subject to abrupt price movements and may be less liquid, which may mean that they are not easy to buy or sell.

The Funds may use derivatives (complex instruments) in an attempt to reduce the overall risk of their investments, reduce the costs of investing and/or generate additional capital or income, although this may not be achieved. The use of such complex instruments may result in greater fluctuations of the value of the Funds. The Manager, however, will ensure that the use of derivatives within the Funds does not materially alter the overall risk profile of the Funds.

As a result of COVID-19, markets have seen a noticeable increase in volatility as well as, in some cases, lower liquidity levels; this may continue and may increase these risks in the future. In addition, some companies are suspending, lowering or postponing their dividend payments, which may cause those funds that have an income objective to pay a lower income during this period.

A more detailed description of risk factors that apply to these Funds is set out in the Prospectus.

Value Assessment (Unaudited)

The Manager conducted an assessment of value for each Fund. The assessment of value report will be made available to investors annually in a composite report for all the funds in Invesco's ICVC range on our website www.invesco.co.uk.

Liability

The Company is structured by having different Funds. The assets and liabilities of each Fund are segregated in accordance with the law of England and Wales. As a consequence the assets of a Fund will not be available to meet the liabilities of another Fund within the Company.

The Shareholders are not liable for the debts of the Company.

Holdings in other Funds of the Company

As at 31 March 2020, no Funds held shares in any other Fund of the Company.

ISA Eligibility

All the Company's Funds qualify for stocks and shares ISA investment.

None of the Funds qualify for cash ISA investment.

Certification of the Annual Report by the Manager In accordance with the requirements of the Open-Ended Investment Companies Regulations 2001, we hereby certify these financial statements on behalf of the Directors of Invesco Fund Managers Limited.

Director - Douglas Sharp

Director - Alan Trotter

28 September 2020

Report of the Authorised Corporate Director (the "Manager")

Risk and Reward Profiles

for the year 1 April 2019 to 31 March 2020

Invesco Income Fund (UK)¹ Lower Risk Typically lower rewards 1 2 3 4 5 6 7

Invesco UK Enhanced Index Fund (UK)

Lower Ri	sk			Hiç	gher Risk	
Typically	lower rev	vards	Typica	ılly highei	rewards	
1	2	3	4	5	6	7

Invesco UK Strategic Income Fund (UK)2

Lower Ri	sk			Hid	gher Risk	
Typically	lower rev	vards	Typica	ılly highe	r rewards	
1	2	3	4	5	6	7

- Effective 30 July 2020 the Invesco Income Fund (UK) changed name to Invesco UK Equity Income Fund (UK)
- ² Effective 31 July 2020 the Invesco UK Strategic Income Fund (UK) merged into Invesco UK Equity Income Fund (UK)

The risk categories shown are not a measure of capital losses or gains, but of how significant the rises and falls in the share class prices have been historically. For example a share class whose price has experienced significant rises and falls will be in a higher risk category, whereas a share class whose price has experienced less significant rises and falls will be in a lower risk category. As the Share Class risk category has been calculated using historical data, it may not be a reliable indication of the Share Class future risk profile. Please note that the Share Class risk category may change in the future and is not guaranteed. The lowest risk category does not mean a risk free investment.

A share class in risk category 1 indicates its price has experienced very low rises and falls historically.

A share class in risk category 2 indicates its price has experienced minor rises and falls historically.

A share class in risk category 3 indicates its price has experienced very moderate rises and falls historically.

A share class in risk category 4 indicates its price has experienced moderate rises and falls historically.

A share class in risk category 5 indicates its price has experienced significant rises and falls historically.

A share class in risk category 6 indicates its price has experienced very significant rises and falls historically.

A share class in risk category 7 indicates its price has experienced major rises and falls historically.

For more information on our Funds' risk and reward profiles, please refer to the most up to date relevant Fund and share class specific Key Investor Information Documents (KIIDs), which are available at www.invesco.co.uk or by contacting us.

Notes applicable to the financial statements of all Funds

1 Accounting Policies

a) Basis of preparation

The financial statements of Invesco Income Fund (UK) and Invesco UK Enhanced Index Fund (UK) have been prepared on a going concern basis, under the historical cost convention as modified by the revaluation of certain financial assets and liabilities held at fair value through profit and loss.

The financial statements of Invesco UK Strategic Income Fund (UK) have been prepared on a basis other than going concern, non-current assets and non-current liabilities have been re-classified as current assets and current liabilities. Costs associated with the termination of this Fund will be borne by the Manager with no provision being made in these financial statements for such costs. The financial statements have also been prepared in accordance with the United Kingdom Generally Accepted Accounting Practice (UK GAAP), as defined within the UK Financial Reporting Standard (FRS 102) and the Statement of Recommended Practice 'Financial Statements of UK Authorised Funds' (the "SORP"), issued by the Investment Management Association (now known as the Investment Association) in May 2014 and updated in June 2017, the COLL and the Company's Instrument of Incorporation and Prospectus.

b) Recognition of revenue

- Dividends on quoted ordinary shares, collective investment schemes and preference shares are recognised when the securities are quoted ex-dividend. Where such securities are not quoted, dividends are recognised when they are declared.
- ii) Interest on bank balances and deposits is recognised on an accruals basis.
- Revenue arising on debt securities is accreted or amortised over the life of such securities and recognised at a consistent rate over the life of the instrument (effective yield accounting). Future cash flow on all debt securities are considered when calculating revenue on an effective yield basis and where purchase costs are considered to reflect incurred credit losses, such losses are taken into account so that interest is recognised at a reasonably expected commercial rate. Accrued interest purchased and sold on interest-bearing securities is excluded from the capital cost of these securities and dealt with as part of the revenue of the Company.
- iv) All revenue is recognised at a gross amount that includes any withholding taxes but excludes any other taxes, such as attributable tax credits.
- v) Returns from derivative securities are taken to capital and/or revenue depending on the motive and circumstances surrounding the particular transaction. The net revenue/expense on derivative positions are recognised as revenue and form part of the Company's distribution.
- vi) Distributions and accumulations, excluding equalisation, receivable on the underlying collective investment schemes are recognised as revenue when the shares are quoted ex-dividend. The Manager rebates an amount equivalent to the ongoing charge suffered on this Fund's share in the underlying collective investment schemes. Each rebate is paid to either the capital or revenue element of the Fund depending on whether the fee of the underlying Fund is charged to capital or revenue.

c) Stock dividends

Ordinary stock dividends are recognised wholly as revenue and are based on the market value of the shares on the dates they are quoted ex-dividend. Where an enhancement is offered, the amount by which the market value of the shares on the date they are quoted ex-dividend exceeds the cash dividend is taken to capital.

d) Special dividends and share buy-backs

The underlying circumstances behind both special dividends and the proceeds from share buybacks are reviewed on a case by case basis in determining whether the amount is capital or revenue in nature. Amounts recognised as revenue will form part of the Company's distribution. Any tax treatment thereon will follow the accounting treatment of the principal amount.

e) Underwriting commission

Underwriting commission is wholly recognised as revenue when the issue takes place, except where the Company is required to take up all or some of the shares underwritten, in which case an appropriate proportion of the commission received is deducted from the cost of those shares.

f) Expenses

All expenses, except for those relating to the purchase and sale of investments, are charged initially against revenue and are accounted for on an accruals basis.

g) Revenue allocation to share classes

Revenue is allocated each day pro rata to the capital value of assets attributable to each class and taxation is computed by reference to the net revenue after expenses and tax attributable to each class.

h) Measurement basis

The measurement basis used in preparing the financial statements is fair value for investments and historical cost for all other assets and liabilities.

Notes applicable to the financial statements of all Funds

1 Accounting Policies continued

i) Basis of valuation of investments

All investments are valued at their fair value as at the balance sheet date.

All investments have been valued on the last business day of the year at bid market value net of any accrued revenue, at close of business. Where there is no price source from an active market for an investment, the Manager will assess any information available from internal and external sources in order to arrive at an estimated fair value. The fair value is established by using measures of value such as the price of recent transactions, earnings multiple and net assets. The Manager of the Company also makes judgements and estimates based on their knowledge of recent investment performance, historical experience and other assumptions that are considered reasonable under the circumstances. The estimates and the assumptions used are under continuous review by the Manager with particular attention paid to the carrying value of the investments. Over-the-counter derivative contracts shall be valued on the basis of unrealised gain or loss on the contract using current settlement price. When settlement price is not used, the over-the-counter derivative contracts will be valued at their fair value in accordance with the method of valuation (as used on a consistent basis) as shall have been agreed between the Manager and the Depositary.

Valuation of unquoted equity instruments

The Fund defines Fair Value in accordance with the definition of Fair Value contained within the International Private Equity and Venture Capital Valuation Guidelines which states that Fair Value is "the price that would be received to sell an asset in an orderly transaction between market participants at the Measurement Date" ("Fair Value"). The fair value of unquoted equity instruments is determined in accordance with International Private Equity and Venture Capital ("IPEV") Valuation Guidelines.

The Fund's Operations Function includes an independent pricing team responsible for valuation of unquoted equity instruments. Unquoted equity investments are stratified according to their risk profile and valuations may be performed internally or outsourced to third party valuation experts. The Fund currently uses Duff & Phelps as its third-party valuation provider. Valuations reports from Duff & Phelps are reviewed and included as an input in the final determination of valuation assessment.

Valuations are reviewed periodically including upon trigger events identified from continuous monitoring of the companies. This is to reflect the latest company developments as well as market conditions in the valuation of the companies. Given the long-term nature of the investments, amounts realised on the sale of these investments may differ from the values reflected in these financial statements and the difference may be material.

All changes in valuation are determined by the Pricing Team and presented for approval to the Unquoted Pricing Committee (UPC). The UPC has an Oversight Function with the following responsibilities:

- Approval of valuation policies and procedures;
- Assessment of the appropriateness of valuation methodologies;
- Approval of valuation changes backed by either internal or external valuation reports from Duff & Phelps:
- Approval of due diligence performed on services provided by third party valuation experts;
- Monitoring timeliness of reviews;
- Retaining independence from the Pricing team and Investment teams

Valuation Methodologies

Unquoted equity instruments are initially recognised at fair value, which is typically the transaction price. On subsequent measurements dates, fair value is determined using applicable and appropriate valuation techniques in line with the IPEV Valuation Guidelines. The selection of valuation techniques includes consideration of factors such as:

- the stage of development of the company;
- the quality and reliability of the data available;
- whether the company is pre-revenue, cash flow negative;
- the relative applicability of the techniques given the nature of the industry and current market conditions;
- the comparability of company or transaction data;

We seek to select valuation techniques that draw heavily on observable market-based measures of risk and return. We also select techniques that will most appropriately reflect the nature, facts and circumstances of the investment and expected view of Market Participants. We typically use multiple valuation techniques to cross check the Fair Value and arrive at a valuation range, from which we conclude at a point in the Valuation Range.

Typically, valuation techniques used include the following:

Notes applicable to the financial statements of all Funds

1 Accounting Policies continued

i) Basis of valuation of investments continued

Milestones Analysis

For early-stage companies and pre-revenue companies, the Milestones Analysis is recognised as an appropriate methodology to value the equity of a company if any material differences in economic rights across share classes are appropriately reflected. The Fair Value indicated by a transaction in the Company's equity can provide a base for recalibrating inputs into the valuation, with qualitative milestones being used to provide directional indication of the movement in Fair Value since that time.

In accordance with IPEV guidelines these include:

- Financial measures: revenue growth, profitability expectations, cash burn rate and covenant compliance;
- Technical measures: phases of development, testing cycles, patent approvals and regulatory approvals;
- Market and sales measures: customer surveys, testing phases, market introductions and market share

Under this methodology we first determine the most Recent Transaction in the shares that was assessed as reflective of Fair Value in accordance with IPEV guidelines. This Transaction is used as a base and the value per share is adjusted as appropriate to reflect any developments or milestones achieved or missed in between the Transaction Date and the Measurement Date. We assess whether any adjustment is required for changes in financial measures, technical measures and market factors.

Scenario Analysis

In estimating Fair Value we may use a Scenario Analysis based on a Probability-Weighted Expected Returns Model ("PWERM") where we consider the present value of the probability-weighted expected payoff to the various share classes in the company's capital structure based on the relevant economic rights and range of estimated exit values.

Earnings Multiple

Under this approach we select a performance measure appropriate for the valuation of the company, such as EBIT, EBITA, EBITDA or Revenue. This is assessed and is adjusted to arrive at a maintainable performance measure. The Multiple is derived from Comparable Companies based on comparability with respect to size, risk profile and earnings growth prospects. The Comparable Company Multiple is typically adjusted for non-marketability and liquidity to arrive at a discounted multiple or an adjusted multiple. The Adjusted Multiple is then applied to the performance measure to derive an enterprise value. Net debt is deducted, and Equity Value allocated according to the seniority of instruments in the capital structure of the company.

Discounted Cash flow Analysis (DCF)

A DCF involves estimating the fair value of a business by calculating the present value of expected future cash flows, based on the most recent forecasts in respect of the underlying business. Because producing reliable cash flow forecasts for seed, start-up and early-stage companies involves a lot of uncertainty and subjectivity given their pre-revenue /negative cashflow status this methodology is infrequently used and may typically be used as a cross check only.

j) Exchange rates

Assets and liabilities in foreign currencies are translated into Sterling at the exchange rates ruling at close of business on the last business day of the year. Revenue items denominated in foreign currencies are translated into Sterling at the exchange rates ruling at the times of the transactions. Foreign exchange gains and losses arising from translation are included in the Statement of Total Return and are included in net capital gains/(losses) on investments.

k) Taxation and deferred taxation

Provision is made for corporation tax at the current rate on the excess of taxable revenue over allowable expenses. Corporation tax is charged at 20% of the revenue liable to corporation tax less expenses. Provision is made on all material timing differences arising from the different treatment of items for accounting and tax purposes. A deferred tax asset is recognised only to the extent that there will be taxable profits in the future against which the asset can be offset. Overseas capital gains tax is accounted for on a cash basis. There is no material difference between recognition of overseas capital gains tax on an accruals or cash basis.

Notes applicable to the financial statements of all Funds

1 Accounting Policies continued

I) Efficient portfolio management

Where appropriate, certain permitted transactions such as derivatives or forward currency transactions are used for efficient portfolio management. Where such transactions are used to protect or enhance revenue, the revenue and expenses derived therefrom are included in 'Revenue' or 'Interest payable and similar charges' in the Statement of Total Return. Where such transactions are used to protect or enhance capital, the gains and losses derived therefrom are included in 'Net capital gains/losses' in the Statement of Total Return. Any positions on such transactions open at the year end are reflected in the Balance Sheet at their marked to market value.

m) Dilution adjustment

The need to apply a dilution adjustment will depend on the volume of sales (where they are issued) or redemptions (where they are cancelled) of shares. The Manager may apply a dilution adjustment on the issue and redemption of such shares if, in its opinion, the existing Shareholders (for sales) or remaining Shareholders (for redemptions) might otherwise be adversely affected, and if applying a dilution adjustment, so far as practicable, it is fair to all Shareholders and potential Shareholders. In particular, the dilution adjustment may be applied in the following circumstances for all Funds in the Invesco UK 2 Investment Series:

- where over a dealing period a Fund has experienced a large level of net issues or redemptions relative to its size. For these purposes a large level of net dealing is defined as 1% or more of the net asset value of the Fund in question (as calculated at the last valuation point); or
- where the Manager considers it necessary to protect the interests of the Shareholders of that Company.

On the occasions that the dilution adjustment is not applied there may be an adverse impact on the total assets of the Fund which may otherwise constrain the future growth of the Fund in question.

Please refer to Appendix 6 of the Prospectus which shows the size of typical dilution adjustments by Fund and an indication of the frequency of application of such adjustments.

2 Distribution Policies

The Funds will distribute all revenue disclosed in the annual financial statements (less expenses and taxation). The ordinary element of stock dividends is treated as revenue and forms part of the Company's distribution. Should expenses and taxation exceed revenue for a share class, there will be no distribution for that share class and the shortfall will be met from capital. All Fund accumulations and distributions are paid as dividend distributions.

In calculating the amount to be distributed, the following Funds allocate the Manager's ongoing charge to capital, thereby increasing the amount available for distribution:

Invesco Income Fund (UK)
Invesco UK Strategic Income Fund (UK)

Distributions which have remained unclaimed by Shareholders for more than six years are credited to the capital property of the Fund.

3 Dealing Charges and Research Payments

The cost of the execution service provided by brokers may be included as part of the spread between the bid and offer price or paid through a separate dealing commission. Dealing commissions are used in the equity securities market, whilst the fixed income market includes the cost of execution in the spread. Prior to 3 January 2018, it was market practice for investment managers to enter into dealing commission arrangements under which as well as paying for execution, part of the commission would be used to pay for research services. This was in accordance with regulation.

The European Union legal framework governing financial markets, known as the Markets in Financial Instruments Directive (MiFID I), has been replaced by a revised Directive (the recast MiFID) and new Regulation (MiFIR) - referred to together as MiFID II. MiFID II became effective on 3 January 2018, and changes the way investment managers operate their businesses. In particular, under MiFID II firms can either pay for research material/services out of their own resources or from a separate research payment account (RPA). From 3 January 2018, the Manager, the Investment Adviser and any sub-adviser pay for all external research materials/services procured for the Funds out of their own resources across equity, fixed income, derivatives and currency securities. They do not operate a RPA.

Notes applicable to the financial statements of all Funds

4 Shareholders' Funds

The Manager's entry charge and Fund Management Fee (FMF) are as follows:

		Entry Charge %	Fund Management Fee %
Invesco Income Fund (UK)	- Trail classes	5.0	1.66
	- No Trail classes	0.0	1.16
	- Z classes	0.0	0.91
	- Y classes	0.0	0.86
Invesco UK Enhanced Index Fund (UK)	 No Trail classes 	0.0	0.25
	- Z classes	0.0	0.24
	- Y classes	0.0	0.23
Invesco UK Strategic Income Fund (UK)	- Trail classes	5.0	1.67
•	- No Trail classes	0.0	1.17
	- Z classes	0.0	0.92
	- Y classes	0.0	0.87

With effect from 4 May 2020, the entry charge was removed from the Trail share classes.

References in this report to Trail classes mean the Accumulation Shares and Income Shares.

The net assets attributable to each share class, the net assets value per share and the number of shares in issue of each share class are shown in the comparative tables of each Fund. These can be found on:

Invesco Income Fund (UK)	pages 18 to 21
Invesco UK Enhanced Index Fund (UK)	pages 39 to 41
Invesco UK Strategic Income Fund (UK)	pages 57 to 60

Each share class has the same rights on a winding up of the Company.

5 Generic Risk Factors

In pursuing their investment objectives, the Funds of the Company hold a number of financial instruments that may comprise securities and other investments, cash balances and debtors and creditors that arise directly from their operations.

Political and economic events in the major economies of the world, such as the United States, Japan and the European Union, will influence stock and securities markets worldwide.

The main risks from the Fund's holding of financial instruments are set out below together with the Manager's policy for managing these risks.

Investing in Financial Derivative instruments

There are certain investment risks which apply in relation to the use of derivatives. Derivatives may be used to provide protection for an investment or as a cheaper or more liquid alternative for an investment. However, should the Manager's expectations in employing such techniques and instruments be incorrect, a Fund may suffer a substantial loss, having an adverse effect on the net asset value of shares. Such instruments may cause greater fluctuations of the net asset value of the Fund concerned. Transactions in derivatives are used in the Funds for efficient portfolio management. Derivatives exposure is managed within the investment limits set by the Manager to ensure that the use of derivatives does not materially alter the overall risk profile of the Fund.

Market price risk

The Funds are exposed to the risks normally associated with investment in stocks and shares such as general economic conditions, market events or the performance of underlying stocks. As such the prices of and the income generated by the Fund's securities may go down as well as up and an investor may not get back the full amount invested.

Adhering to investment guidelines and avoiding excessive exposure to one particular issuer can mitigate market risk.

Currency exchange risk

The Funds may invest in securities denominated in currencies other than Sterling. As a result, changes in exchange rates may adversely affect the value of any investment, which will have a related effect on the price of shares.

Currency exchange risk may be mitigated by hedging the exposure through the use of forward currency contracts.

Notes applicable to the financial statements of all Funds

5 Generic Risk Factors continued

Custody risk

The assets owned by each Fund are held on trust for the Fund by a custodian that is also regulated by the Financial Conduct Authority. The Financial Conduct Authority requires that the custodian ensures that there is legal separation of non-cash assets held under custody and that records are maintained that clearly identify the nature and amount of all assets under custody, the ownership of each asset and where the documents of title to that asset are located. In case of a potential bankruptcy of the custodian, cash positions in the Fund are not protected and there may be a delay in regaining full control of the non-cash assets.

Liquidity risk

The Funds may be affected by a decrease in market liquidity for the securities in which they invest, which may mean that the Funds may not be able to sell some securities at a fair price within a timely manner. In order to mitigate this risk, a substantial proportion of the Fund's assets consist of readily realisable assets.

Furthermore, Invesco monitors liquidity risk for each portfolio against its required minimum liquidity threshold. This includes holding a high enough proportion of assets that can be liquidated quickly and with a limited impact on price, also depending on its actual or hypothetical redemption profile, investment strategy, regulatory framework or contractual obligations. This is done by implementing a monitoring framework focused on Liquidation Size and Liquidation Cost.

Liquidity results are monitored at the Fund level on a daily basis including against internally defined limits.

Counterparty risk

The Funds may enter into derivatives transactions or place cash in bank deposit accounts, which would expose the Funds to the credit of its counterparties and their ability to satisfy the terms of such contracts. In the event of a bankruptcy or insolvency of a counterparty, the Funds could experience delays in liquidating positions and significant losses, including declines in the value of investments during the period in which the Funds seek to enforce its rights, inability to realise any gains on its investments during such period and fees and expenses incurred in enforcing its rights.

In order to mitigate this risk, the Funds conduct trades through reputable counterparties. A diligent process to select and approve a new counterparty, as well as monitoring existing counterparties, is in place. During the approval process, various verifications are performed such as assessing the counterparty's operational capabilities as well as its credit quality. On an ongoing basis, market analysis is reviewed by the firm's trading and credit research teams in order to detect warning signs of a counterparty default. If the firm believes high risk of default exists, the counterparty is removed with immediate effect from the approved counterparty list.

Taking charges from capital

Where the investment objective of a Fund is to treat the generation of income as a higher priority than capital growth, or the generation of income and capital growth have equal priority, all or part of the ongoing charge as well as other fees and expenses of the Funds may be taken from capital instead of income. The Funds take such fees and expenses from capital in order to manage the level of income paid and/or available to Shareholders. This may result in capital erosion or may constrain capital growth.

Calculation methods of the Risk Exposure

Following the assessment of the investment policy of each Fund of the Company, Invesco Fund Managers Limited has decided to use Value at Risk (VaR) for the assessment of the global exposure of each Fund.

Value-at-Risk (VaR) is a statistical measurement. It intends to measure the maximum potential loss at a given confidence level (probability) over a specific time period under normal market conditions. All of the positions within the portfolio are taken into account for the VaR calculation, not just derivatives.

Absolute and Relative VaR are calculated daily using a VaR risk model based on a two years historical simulation methodology. This method for calculating VaR contains no standard distribution assumption and assumes that history repeats itself.

Notes applicable to the financial statements of all Funds

5 Generic Risk Factors continued

Calculation methods of the Risk Exposure continued

Under the relative VaR approach, the VaR of the Fund is compared to that of a benchmark or reference portfolio. With this approach the choice of benchmark is important and hence the Manager will choose a leverage free benchmark with similar risks to the Fund.

The calculation standards used for the VaR model are in compliance with the provisions in box 15 of ESMA Guidelines on Risk Measurement and the calculation of Global Exposure and Counterparty Risk for UCITS (Ref: 10-788) ("ESMA Guidelines").

The Absolute VaR of a UCITS cannot be greater than 20% of its NAV. The Relative VaR of a UCITS cannot be more than two times the VaR of the reference portfolio. Invesco Fund Managers Limited monitors that the (VaR of the UCITS)/(2* VaR of the reference portfolio) is not greater than 100%.

The calculation of the Absolute and Relative VaR is carried out in accordance with the following parameters:

- one-tailed confidence interval of 99%;
- holding period equivalent to one month (i.e. 20 business days);
- effective observation period (history) of risk factors of two years;
- daily calculation.

In line with box 25 of ESMA Guidelines, as the Funds use the VaR approach to monitor the global exposure, Invesco Fund Managers Limited calculates the leverage for each Fund on a daily basis, as the sum of the absolute value of the notionals of the derivatives used. With respect to financial derivative instruments which do not have a notional value attached to them, the calculation of the value is based upon the market value of the equivalent position of the underlying asset that is attached to the financial derivative instrument and applied consistently and appropriately.

The average level of leverage figures provided below does not take into account any netting and hedging arrangements that the Funds may have in place at any time even though these netting and hedging arrangements are used for risk reduction purpose.

The table below details the VaR approach for each Fund and, for those Funds utilising the relative VaR methodology, it details the reference portfolio. The table also details the minimum, maximum and average daily VaR utilisation that occurred during the one year period ending 31 March 2020, as well as the daily average level of leverage for each Fund during the one year period ending 31 March 2020.

		Global Exposure							Leve	erage	
		Method used to	Method used to		Reference portfolio for using Relative VaR limit VaR financial		limits reached for last ncial year		VaR limits	Leverage level reached during the	
Fund name	Period of Obser- vation	calculate Global exposure (Commit ment, Absolute VaR, Relative VaR)	Type of model (Historical simulation, Monte Carlo)	Parameters (Confidence holding per observation	e Interval, iod,	Lowest	Highest	Average (based on daily data)	Regulatory limits	financial year (Average levels as a % of NAV, calculated at least twice per month)	Leverage calculation method used
Invesco Income Fund (UK)	1 April 2019 - 31 March 2020	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	Share Index	36.5%	51.6%	40.2%	100%	0%	Sum of the Notional of the derivatives
Invesco UK Enhanced Index Fund (UK)	1 April 2019 - 31 March 2020	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	Share (ex Invest	47.4%	52.1%	49.1%	100%	3%	Sum of the Notional of the derivatives
Invesco UK Strategic Income Fund (UK)	1 April 2019 - 31 March 2020	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	Share Index	36.9%	54.0%	44.5%	100%	0%	Sum of the Notional of the derivatives

Notes applicable to the financial statements of all Funds

5 Generic Risk Factors continued

Calculation methods of the Risk Exposure continued

The table below details the VaR approach for each Fund and, for those Funds utilising the relative VaR methodology, it details the reference portfolio. The table also details the minimum, maximum and average daily VaR utilisation that occurred during the one year period ending 31 March 2019, as well as the daily average level of leverage for each Fund during the one year period ending 31 March 2019.

			Global Exposure							Leve	Leverage	
		Method	Method used to		Reference portfolio for using Relative VaR	for using Relative VaR limits reached			VaR limits	Leverage level reached		
Fund name	used to calculate Global exposure (Commit ment, Absolute Period of VaR, Obser- Relative vation VaR)		Type of model (Historical simulation, Monte Carlo)	Parameters (Confidence holding per observation	e Interval, iod, n period)	Lowest	Highest	Average (based on daily data)	Regulatory limits	during the financial year (Average levels as a % of NAV, calculated at least twice per month)	Leverage calculation method used	
Invesco Income Fund (UK)	1 April 2018 - 31 March 2019	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	FTSE All- Share Index	40.2%	52.0%	45.3%	100%	0%	Sum of the Notional of the derivatives	
Invesco UK Enhanced Index Fund (UK)	1 April 2018 - 31 March 2019	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	FTSE All- Share Index	49.6%	59.7%	54.6%	100%	3%	Sum of the Notional of the derivatives	
Invesco UK Strategic Income Fund (UK)	1 April 2018 - 31 March 2019	Relative VaR	Historical Simulation	99% confidence level, 20 days, 2 years of risk factors	FTSE All- Share Index	35.4%	48.6%	41.1%	100%	0%	Sum of the Notional of the derivatives	

Notes applicable to the financial statements of all Funds

6 Investment Objective and Policy

The investment objective and policy of each Fund can be found on:

Invesco Income Fund (UK)page 16Invesco UK Enhanced Index Fund (UK)page 37Invesco UK Strategic Income Fund (UK)page 55

The Funds may also hold cash and near cash assets only to the extent that this may reasonably be regarded as necessary for the pursuit of the Fund's investment objective, to fund redemptions of shares in that Fund, for the efficient management of the Fund in accordance with its investment objective or for other purposes which may reasonably be regarded as ancillary to the investment objectives of the Fund. They may also borrow, provided such borrowing is on a temporary basis and does not exceed the limits laid down in the regulations.

7 Base Currency

The base currency of the Company is Sterling and is taken to be the 'functional currency' of the Company.

8 Bank Balances and Overdrafts

Bank balances and overdrafts are held by the Custodian, and are subject to the Custodian's variable credit and debit interest rates respectively.

9 Borrowings

The borrowing facilities available to the Company as at 31 March 2020 comprise a bank overdraft facility of up to 10% of the value of the Company (31 March 2019 - 10%).

10 Transactions and Balances with Related Parties

Invesco Fund Managers Limited (and its associates), as Manager, is a related party and acts as principal in respect of all transactions in the shares of the Company.

Amounts payable to Invesco Fund Managers Limited in respect of Fund Management Fees are disclosed in note 4, within each Fund. Management fee rebates are disclosed in note 3 within each Fund. Amounts due at the end of the accounting year in relation to the Fund Management Fees are disclosed in note 10 within accrued expenses, within each Fund.

All issued and redeemed shares transacted with the ACD are shown in the Statement of Change in Net Assets Attributable to Shareholders and balances due from and to the ACD are shown in notes 8 and 10 to the financial statements of each Fund.

Invesco Fund Managers Limited and its associates (including other authorised investment companies managed by Invesco Fund Managers Limited) held the following shareholdings in the Funds:

Held at 31.3.20	Change in year	Held at 31.3.19
1,214,707	1,214,707	_
2,669,605	(393,810)	3,063,415
-	(837)	837*
-	(1,000)	1,000*
794	-	794
-	(5,000)	5,000*
-	(5,000)	5,000*
-,,		7,503,943
7,698,791	(5,945,817)	13,644,608
40.057.000	(0.440.000)	16 576 701
13,957,892	(2,618,829)	16,576,721
	31.3.20 1,214,707	31.3.20 year 1,214,707 1,214,707 2,669,605 (393,810) - (837) - (1,000) 794 -

^{*} Seed Capital Investment.

Invesco UK 2 Investment Series (the "Company")
Notes applicable to the financial statements of all Funds

11 Post Balance Sheet Events

Effective 31 July 2020 the Invesco UK Strategic Income Fund (UK) merged into the Invesco UK Equity Income Fund (UK).

Investment report for the year

The Investment Objective and Policy of the Invesco Income Fund (UK)

The Fund aims to achieve a reasonable level of income together with capital growth over the long term (5 years plus). The Fund invests at least 80% of its assets in shares or other equity related securities of companies incorporated, domiciled or carrying out the main part of their economic activity in the UK. In pursuing the Fund's investment objective, the fund manager may consider it appropriate to also invest in other transferable securities (including private and unlisted equities and non UK companies), money-market instruments, collective investment schemes (including funds managed by the Invesco group), deposits and cash. The Fund may use derivatives for efficient portfolio management purposes only, to reduce risk, reduce costs and/or generate additional capital or income.

On the 7 August 2019 there was an update to the Prospectus for the various ICVC funds in light of the FCA's Asset Management Market Study. As part of this update, various changes were implemented regarding the Fund's investment objectives, investment policies, investment strategies and benchmark disclosures, all for clarification purposes only. There has been no changes to the way the Funds are managed as a result of these changes. The updated prospectus is available at www.invesco.co.uk. The investment objectives and policies currently shown within these financial statements are those that were in place as at 31 March 2020.

Performance ¹		"	"	Perc	entage growth
to 31 March 2020	Since 30.9.19 %	Since 31.3.19 %	Since 31.3.17 %	Since 31.3.15 %	Since 31.3.10 %
Invesco Income Fund (UK)					
(Z Accumulation shares) ²	-32.44	-33.87	-37.21	-32.17	26.84
IA UK All Companies Sector NR ³	-22.98	-19.15	-14.56	-1.57	56.15
Fund Ranking	230/239	230/237	220/227	210/214	158/172

Standardised rolling 12 month performance Percentage growth							
	31.3.15	31.3.16	31.3.17	31.3.18	31.3.19		
	31.3.16	31.3.17	31.3.18	31.3.19	31.3.20		
	%	%	%	%	%		
Invesco Income Fund (UK)							
(Z Accumulation shares) ²	-2.2	10.5	-6.3	1.3	-33.9		
IA UK All Companies Sector NR ³	-2.5	18.1	2.7	2.9	-19.2		

This standardised past performance information is updated on a quarterly basis. Should you require up to date past performance information, this is available on our website www.invesco.co.uk or by contacting us.

Fund and sector average performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. This may differ from the performance figure shown on page 19 for Z Accumulation shares as the figure above is based on the quoted 12pm price and the figure shown on page 19 is based on the close of business bid price.

The value of investments and any income from them will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.

Past performance is not a guide to future returns. Current tax levels and reliefs may change. Depending on individual circumstances, this may affect investment returns.

- ¹ Performance based on the Published Net Asset Value.
- Effective 18 April 2016, the primary share class changed from Income share class to Z Accumulation share class. Performance figures are based on the Z Accumulation share class. As this was launched on 12 November 2012, for the periods prior to this launch date, performance figures are based on the Income share class, without any adjustment for fees.
- This is a Comparator Benchmark. Given its geographic focus the Fund's performance can be compared against the Benchmark. However, the Fund is actively managed and is not constrained by any benchmark.

Investment report for the year

Strategy, review and outlook

The Fund fell in value during the year to the end of March 2020, under-performing the IA UK All Companies Sector NR.

Fund and sector average performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. Performance figures are based on the Z Accumulation share class.

Past performance is not a guide to future returns.

It has been a volatile 12 months for the UK equity market, dominated by concerns affecting the outlook for global economic growth. US-China trade relations, Brexit, and domestic politics were huge uncertainties in 2019, but 2020 so far has delivered the market shock that no one could have foreseen. The UK equity market fell in the first quarter of 2020 posting its biggest quarterly drop for more than three decades as the global economic costs of the Covid-19 pandemic continued to mount. Extreme levels of volatility were witnessed on an intraday basis, with swings in prices significantly large enough to impact 12-month returns.

Prior to the pandemic, employment growth in the UK looked set to remain firm, real wages were set to increase further, growth in government spending had picked up and investment spending was likely to strengthen. On this basis, overall rates of economic growth were expected to accelerate throughout the year. As the scale of the pandemic unfolded, however, governments around the world launched unprecedented stimulus measures in March, while central banks cut interest rates to support economic activity in the coming months. The strength and depth of the measures announced by the Chancellor and the Bank of England should provide material support to employment income and bank lending to the real economy.

Looking at the four main themes within the Fund: UK Domestic Value, International Growth Opportunities, Tobacco and Non-Correlated Financials, it follows that a number of companies within the UK Domestic Value theme performed positively over the 12 months. Tesco, Derwent London, Cranswick, Breedon and Whitbread all delivered positive returns, benefiting from the Conservative Party's emphatic election victory in December 2019 and greater clarity around Brexit. However, stocks within the theme which are more heavily exposed to Sterling weakness, or those which have suffered from the impact of the virus, have tended to underperform (Capita, Next).

Some of the better performing stocks also included those within the International Growth Opportunities and Tobacco themes. Tobacco and Oil stocks, for example, tend to be more exposed to international earnings, which means that they are relative beneficiaries of \$US strength (British American Tobacco, Total, and Royal Dutch Shell). The International Growth Opportunities theme also includes HomeServe, a company engaged in providing home emergency, repair and heating installation services, and select health care stocks such as Novo Nordisk and Novartis, which have performed well. Health care is one of only two sectors to have delivered positive returns at the broad market level over the 12-month period. The absence of AstraZeneca and GlaxoSmithKline, however, impacted performance relative to the benchmark. Elsewhere, easyJet and International Consolidated Airlines (IAG) also saw

significant share price falls. The spread of Covid-19 and the measures to contain it have had a significant impact on the share price of the tourism and leisure industry (which includes air travel).

Meanwhile, the Non-Correlated Financials theme has exhibited a particularly wide range of outcomes. The investment platform AJ Bell, a longstanding investment for the Fund, saw strong share price growth, and online trading platform Plus500 performed well due to increased trading on CFDs (contract for difference) by people isolating at home. On the flipside, non-prime lenders such as Provident Financial tended to be weaker.

The Fund's positioning has evolved incrementally over the past year to best reflect the opportunities that the fund manager has seen in the market. It is frustrating that the performance of the Fund has lagged the wider stock market, however the fund manager remains confident in the composition of the Fund and believes that it is crucial, in such times of extreme volatility and somewhat irrational market pricing, that the Fund remains rooted in the fundamental investment process.

The Fund continues to seek to invest in companies that have the potential to achieve both capital growth and sustainable growth in income over time. In investing across the market-cap spectrum, the risk profile of the Fund is diversified, whilst also benefitting from diverse sources of income. The fund manager continues to seek the best opportunities to create a diversified, sustainable flow of dividend income that can grow over time.

Mark Barnett, Fund Manager

Where Mark Barnett has expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.

Effective 15 May 2020 Mark Barnett left Invesco, James Goldstone and Ciaran Mallon were appointed as Fund Managers.

The Fund's ten largest investments are	%
British American Tobacco	7.04
BP	6.38
PureTech Health	3.85
Tesco	3.59
Oxford Nanopore Technologies	3.39
Derwent London	3.08
Legal & General	3.02
Next	2.68
Royal Dutch Shell	2.59
Cranswick	2.53

Investment report for the year

Comparative tables			
Year ended Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	3,178.95	3,140.89	3,385.25
Return before operating charges*	(949.08)	92.12	(188.01)
Operating charges	(50.77)	(54.06)	(56.35)
Return after operating charges	(999.85)	38.06	(244.36)
Distributions	(111.09)	(114.96)	(109.92)
Retained distributions on	111.00	11100	100.00
accumulation shares	111.09	114.96	109.92
Closing net asset value per share	2,179.10	3,178.95	3,140.89
*After direct transaction costs of	(3.46)	(2.57)	(2.97)
Performance			
Return after charges	(31.45%)	1.21%	(7.22%)
Other information			
Closing net asset value (£'000)	688,313	1,393,719	1,891,056
Closing number of shares	31,587,102	43,842,078	60,207,580
Operating charges	1.66%	1.66%	1.66%
Direct transaction costs Performance fee	0.11%	0.08%	0.09%
Prices			
Highest share price	3,269.90	3,429.56	3,562.99
Lowest share price	1,934.77	2,997.13	3,107.99
Year ended Accumulation shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share	•••••	•	
Opening net asset value per share	177.67	174.67	187.31
Return before operating charges*	(53.27)	5.11	(10.46)
Operating charges	(1.99)	(2.11)	(2.18)
Return after operating charges	(55.26)	3.00	(12.64)
Distributions	(6.23)	(6.41)	(6.10)
Retained distributions on	6.22	C 44	6.10
accumulation shares	6.23	6.41	6.10
Closing net asset value per share	122.41	177.67	174.67
*After direct transaction costs of	(0.19)	(0.14)	(0.16)
Performance			
Return after charges	(31.10%)	1.72%	(6.75%)
Other information			
Closing net asset value (£'000)	91,358	95,562	140,300
Closing number of shares	74,633,605	53,786,968	80,324,928
Operating charges	1.16%	1.16%	1.16%
Direct transaction costs Performance fee	0.11%	0.08%	0.09%
Prices			
Highest share price	182.79	191.04	197.32
Lowest share price	108.66	167.29	172.82

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued		-	
Year ended Z Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share		•••••	
Opening net asset value per share	314.28	308.19	329.68
Return before operating charges*	(94.46)	9.01	(18.47)
Operating charges	(2.76)	(2.92)	(3.02)
Return after operating charges	(97.22)	6.09	(21.49)
Distributions	(11.04)	(11.34)	(10.75)
Retained distributions on accumulation shares	11.04	11.34	10.75
Closing net asset value per share	217.06	314.28	308.19
Closing het asset value per share	217.00	314.20	300.19
*After direct transaction costs of	(0.34)	(0.25)	(0.29)
Performance			
Return after charges	(30.93%)	1.98%	(6.52%)
Other information			
Closing net asset value (£'000)	149,155	289,207	361,939
Closing number of shares	68,715,030	92,023,288	117,440,679
Operating charges	0.91%	0.91%	0.91%
Direct transaction costs Performance fee	0.11%	0.08%	0.09%
Prices			
Highest share price	323.38	337.36	347.44
Lowest share price	192.68	295.73	304.91
Year ended Y Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share		•••••••••••••••••••••••••••••••••••••••	
Opening net asset value per share	238.47	233.73	249.91
Return before operating charges*	(71.70)	6.83	(14.02)
Operating charges	(1.98)	(2.09)	(2.16)
Return after operating charges	(73.68)	4.74	(16.18)
Distributions	(8.38)	(8.60)	(8.15)
Retained distributions on			
accumulation shares	8.38	8.60	8.15
Closing net asset value per share	164.79	238.47	233.73
*After direct transaction costs of	(0.26)	(0.19)	(0.22)
Performance			
Return after charges	(30.90%)	2.03%	(6.47%)
Other information			
Closing net asset value (£'000)	197,914	473,478	595,525
Closing number of shares	120,100,464	198,551,883	254,791,348
Operating charges	0.86%	0.86%	0.86%
Direct transaction costs Performance fee	0.11%	0.08%	0.09%
Prices			
Highest share price	245.38	255.90	263.39
Lowest share price	146.27	224.36	231.24

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued			
Year ended Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	1,572.49	1,609.49	1,794.16
Return before operating charges*	(460.56)	48.82	(97.28)
Operating charges	(24.86)	(27.44)	(29.60)
Return after operating charges	(485.42)	21.38	(126.88)
Distributions	(54.46)	(58.38)	(57.79)
Retained distributions on			
accumulation shares Closing net asset value per share	1,032.61	1,572.49	1,609.49
orosing net asset value per snare	1,002.01	2/012.47	2,000,145
*After direct transaction costs of	(1.69)	(1.30)	(1.56)
Performance	(20.070()	1 220/	(7.070/)
Return after charges	(30.87%)	1.33%	(7.07%)
Other information	2.47.2.40	500.057	620.664
Closing net asset value (£'000)	247,348	509,857	639,664
Closing number of shares Operating charges	23,953,618 1.66%	32,423,581 1.66%	39,743,276 1.66%
Direct transaction costs	0.11%	0.08%	0.09%
Performance fee	-	-	-
Prices			
Highest share price	1,617.42	1,757.39	1,888.42
Lowest share price	937.80	1,506.11	1,617.69
Year ended Income shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	115.69	117.83	130.69
Return before operating charges*	(34.04)	3.56	(7.13)
Operating charges	(1.28)	(1.41)	(1.51)
Return after operating charges	(35.32)	2.15	(8.64)
Distributions	(4.02)	(4.29)	(4.22)
Retained distributions on			
accumulation shares Closing net asset value per share	76.35	115.69	117.83
		113.07	
*After direct transaction costs of	(0.12)	(0.10)	(0.11)
Performance Return after charges	(30.53%)	1.82%	(6.61%)
Other information	(30.3370)	1.0270	(0.0170)
Closing net asset value (£'000)	37,765	18,969	85,767
Closing number of shares	49,460,004	16,396,607	72,791,492
Operating charges	1.16%	1.16%	1.16%
Direct transaction costs	0.11%	0.08%	0.09%
Performance fee	_	_	_
Prices			
Highest share price	119.02	128.87	137.67
Lowest share price	69.33	110.66	118.41

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued			
Year ended Z Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	253.95	257.99	285.44
Return before operating charges*	(74.88)	7.79	(15.62)
Operating charges	(2.21)	(2.42)	(2.59)
Return after operating charges	(77.09)	5.37	(18.21)
Distributions Data in a distribution and a	(8.84)	(9.41)	(9.24)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	168.02	253.95	257.99
*After direct transaction costs of	(0.27)	(0.21)	(0.25)
Performance	(0.21)	(0.21)	(0.23)
Return after charges	(30.36%)	2.08%	(6.38%)
Other information	(00.0070)	2.0070	(0.0070)
Closing net asset value (£'000)	56,138	181,063	277,395
Closing number of shares	33,410,813	71,298,264	107,520,835
Operating charges	0.91%	0.91%	0.91%
Direct transaction costs	0.11%	0.08%	0.09%
Performance fee	_	_	_
Prices			
Highest share price	261.30	282.41	300.82
Lowest share price	152.56	242.76	259.26
Year ended Y Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	199.35	202.42	223.84
Return before operating charges*	(58.80)	6.12	(12.25)
Operating charges	(1.64)	(1.80)	(1.92)
Return after operating charges	(60.44)	4.32	(14.17)
Distributions	(6.94)	(7.39)	(7.25)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	131.97	199.35	202.42
*After direct transaction costs of	(0.22)	(0.16)	(0.20)
Performance			
Return after charges	(30.32%)	2.13%	(6.33%)
Other information			
Closing net asset value (£'000)	99,995	256,327	320,421
Closing number of shares	75,771,732	128,580,397	158,295,085
Operating charges	0.86%	0.86%	0.86%
Direct transaction costs	0.11%	0.08%	0.09%
Performance fee	-	-	_
Prices	205 12	221 61	225.02
Highest share price Lowest share price	205.12 119.82	221.61 190.54	235.93 203.41
Lowest share price	117.02	170.04	203.41

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Invesco Income Fund (UK)
Investment report for the year

Peetinest	Portfolio Statement (Unaudited) as at 31 March 2020	Holding or nominal value of	Market value	Percentage of total net assets
Financials 2.49% (31.3.19 - 0.00%)	Investment Denmark 2.49% (31.3.19 - 0.00%)	positions	£'000	%
Novo Nordisk 'B' 806,777 39,015 2.49	Financials 2.49% (31.3.19 - 0.00%)			
Prance 1.99% (31.3.19 - NII) Oil & Gas 1.99% (31.3.19 - NII) Total 998.385 31.152 1.99			- 39.015	
Dil & Cas 1.99% (31.3.19 - Nil) Total 998,385 31,152 1.99 1.	NOVO NOTATISK D	000,777	37,013	۷.47
Total 998,385 31,152 1.99				
Cermany 0.00% (31.3.19 - 0.00%) Financials 0.00% (31.3.19 - 0.00%) Speymill Deutsche Immobilien! 14,588,469 - 0.00 Cuernsey 1.84% (31.3.19 - 1.04%) Industrials 0.29% (31.3.19 - 1.04%) Industrials 0.29% (31.3.19 - 1.04%) Industrials 0.29% (31.3.19 - 1.04%) Sherborne Investors 38,879,573 10,731 0.69 Sherborne Investors 14,719,465 13,542 0.86 Israel Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.03%) Switzerland 1.75% (31.3.19 - 0.03%) Switzerland 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Financials Nil	•	998.385	31.152	1.99
Financials 0.00% (31.3.19 - 0.00% Speymill Deutsche Immobillen			,	
Speymill Deutsche Immobilien¹ 14,588,469 - 0.00				
Industrials 0.29% (31.3.19 - 1.04%)	· · · · · · · · · · · · · · · · · · ·	14,588,469	-	0.00
Industrials 0.29% (31.3.19 - 1.04%)	•			
Amedeo Air Four Plus 12,710,658 4,576 0.29				
Sherborne Investors 14,719,465 13,542 0.68 Israel Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Oli & Gas 8.97% (31.3.19 - 91.78%) Financials Nil (31.3.19 - 91.78%) Oli & Gas 8.97% (31.3.19 - 91.78%) Oli & Gas 9.97% (31.3.19 - 91.78%) Oli & Gas 9.97		12,710,658	4,576	0.29
Sherborne Investors 14,719,465 13,542 0.68 Israel Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Oli & Gas 8.97% (31.3.19 - 91.78%) Financials Nil (31.3.19 - 91.78%) Oli & Gas 8.97% (31.3.19 - 91.78%) Oli & Gas 9.97% (31.3.19 - 91.78%) Oli & Gas 9.97	Financials 1 EE04 (21 2 10 - 1 6004)			
Israel Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.36%) Financials Nil (31.3.19 - 0.43%) Financials Nil (31.3.19 - 0.43%) Financials Nil (31.3.19 - 0.00%) Financials Nil (31.3.19 - 0.34%) Financials Nil (31.3.19 - 0.00%) Financials Nil (31		38,879,573	10,731	0.69
Norway Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.043%) Switzerland 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Novartis	Trian Investors	14,719,465	13,542	0.86
Norway Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.43%) Industrials Nil (31.3.19 - 0.043%) Switzerland 1.75% (31.3.19 - 0.00%) Health Care 1.75% (31.3.19 - 0.00%) Novartis	Israel Nil (31 3 19 - 0 36%)			
Novartis Alia Ali				
Novartis A13,110 27,489 1.75				
Novartis 413,110 27,489 1.75				
Oil & Gas 8.97% (31.3.19 - 8.34%) BP 29,133,034 100,057 6.38 Royal Dutch Shell 'A' (UK Regd.) 772,687 10,964 0.70 Royal Dutch Shell 'B' (UK Regd.) 2,177,041 29,599 1.89 Industrials 7.60% (31.3.19 - 11.33%) Babcock International 6,526,967 24,966 1.59 Breedon 49,397,002 32,997 2.11 Capita 35,528,006 11,618 0.74 G4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexcon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.7	· · · · · · · · · · · · · · · · · · ·	413,110	27,489	1.75
Oil & Gas 8.97% (31.3.19 - 8.34%) BP 29,133,034 100,057 6.38 Royal Dutch Shell 'A' (UK Regd.) 772,687 10,964 0.70 Royal Dutch Shell 'B' (UK Regd.) 2,177,041 29,599 1.89 Industrials 7.60% (31.3.19 - 11.33%) Babcock International 6,526,967 24,966 1.59 Breedon 49,397,002 32,997 2.11 Capita 35,528,006 11,618 0.74 G4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexcon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.7				
BP Royal Dutch Shell 'A' (UK Regd.) 29,133,034 772,687 10,964 772,687 10,964 0.70 6.38 Royal Dutch Shell 'B' (UK Regd.) 2,177,041 29,599 1.89 Industrials 7.60% (31.3.19 - 11.33%) Babcock International 6,526,967 24,966 1.59 Breedon 49,397,002 32,997 2.11 232,997 2.11 Capita 35,528,006 11,618 0.74 0.74 G4S 16,589,317 15,305 0.98 15.00 28,284 1.80 HomeServe 2,673,296 28,284 1.80 28,284 1.80 Stobart 1.95% (31.3.19 - 10.10%) US 110,446 7.04 British American Tobacco 4,006,029 110,446 7.04 7.04 Consumer Goods 11.95% (31.3.19 - 10.10%) US 110,446 7.04 British American Tobacco 4,006,029 110,446 7.04 7.04 Countryside Properties 5,758,789 16,413 1.05 7.78,789 16,413 1.05 Victoria 9,632,606 20,132 1.28 1.80 Health Care 3.78% (31.3.19 - 4.98%) 39,632,606 20,132 1.28 Cell Medica 'A' pref.¹ 2 261,841 26 0.00 0.00 Cell Medica 'B' pref.¹ 2 261,841 26 0.00 0.00 Cell Medica 'B' pref.¹ 3 368,980 417 0.03 1.01 Islamin 'B'¹ 368,980 417 0.03 1.01 Islamin 'B'¹ 368,980 417 0.03 0.01				
Royal Dutch Shell 'B' (UK Regd.) 2,177,041 29,599 1.89	BP		•	
Industrials 7.60% (31.3.19 - 11.33%) Babcock International 6,526,967 24,966 1.59 Breedon 49,397,002 32,997 2.11 Capita 35,528,006 11,618 0.74 C4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 7.04 7.04 7.05 7.58,789 16,413 1.05 7.05		· ·		
Babcock International 6,526,967 24,966 1.59 Breedon 49,397,002 32,997 2.11 Capita 35,528,006 11,618 0.74 G4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'B' pref.¹ 368,980 417 0.03	•	2/11/011	27,077	1.07
Breedon 49,397,002 32,997 2.11 Capita 35,528,006 11,618 0.74 G4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Conswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 270,340 - 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹		6 526 967	24 966	1 59
G4S 16,589,317 15,305 0.98 HomeServe 2,673,296 28,284 1.80 Stobart 12,703,197 6,021 0.38 Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D-1¹¹ 13,461 - 0.00 infirst 'D-1¹¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,		49,397,002		
HomeServe Stobart 2,673,296 28,284 1.80 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 6,021 0.38 12,703,197 10,046 7.04 7.04 7.04 7.04 7.04 7.04 7.04 7.04 7.05				
Consumer Goods 11.95% (31.3.19 - 10.10%) British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOx				
British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'B-1' pref.¹ 40,832 1,129 <td>Stobart</td> <td>12,703,197</td> <td></td> <td>0.38</td>	Stobart	12,703,197		0.38
British American Tobacco 4,006,029 110,446 7.04 Countryside Properties 5,758,789 16,413 1.05 Cranswick 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'B-1' pref.¹ 40,832 1,129 <td>Consumer Goods 11.95% (31.3.19 - 10.10%)</td> <td></td> <td></td> <td></td>	Consumer Goods 11.95% (31.3.19 - 10.10%)			
Cranswick Nexeon¹ 1,071,914 39,639 2.53 Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04				
Nexeon¹ 184,981 786 0.05 Victoria 9,632,606 20,132 1.28 Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	•			
Health Care 3.78% (31.3.19 - 4.98%) Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'Pref.¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	Nexeon ¹	184,981	786	0.05
Cell Medica 'A' pref.¹ 727,272 36 0.00 Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'Pref.¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	Victoria	9,632,606	20,132	1.28
Cell Medica 'B' pref.¹ 261,841 26 0.00 Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'Pref.¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	Health Care 3.78% (31.3.19 - 4.98%)			
Cell Medica 'C' pref.¹ 549,507 121 0.01 Flarin 'B'¹ 368,980 417 0.03 infirst 'D'¹ 270,340 - 0.00 infirst 'D-1'¹ 13,461 - 0.00 infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	•	-		
infirst 'D'1 270,340 - 0.00 infirst 'D-1'1 13,461 - 0.00 infirst Pref.1 368,980 1,288 0.08 Lamellar Biomedical1 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies1 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.1 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.1 21,213 609 0.04				
infirst 'D-1'1 13,461 - 0.00 infirst Pref.1 368,980 1,288 0.08 Lamellar Biomedical1 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies1 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.1 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.1 21,213 609 0.04			417	
infirst Pref.¹ 368,980 1,288 0.08 Lamellar Biomedical¹ 39,090 103 0.01 Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04			-	
Mereo Biopharma 4,774,898 859 0.05 Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	infirst Pref. ¹		1,288	
Open Orphan 19,612,195 1,216 0.08 Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04				
Oxford Nanopore Technologies¹ 1,142,539 53,128 3.39 PsiOxus Therapeutics 'A' pref.¹ 40,832 1,129 0.07 PsiOxus Therapeutics 'B-1' pref.¹ 21,213 609 0.04	,			
PsiOxus Therapeutics 'B-1' pref. ¹ 21,213 609 0.04	Oxford Nanopore Technologies ¹	1,142,539	53,128	3.39

Invesco Income Fund (UK)
Investment report for the year

Portfolio Statement (Unaudited) continued as at 31 March 2020	Holding or nominal	Market	Percentage of total
Investment	value of positions	value £'000	net assets %
Consumer Services 11.40% (31.3.19 - 9.19%)	positions	2 000	70
Card Factory	21,709,522	7,129	0.45
easyJet	3,744,675	21,382	1.36
International Consolidated Airlines (UK Regd.)	6,335,091	13,627	0.87
ITWP Acquisitions ¹	2,722,975,639	11,709	0.75
Next	1,032,627	42,049	2.68
Supponor ¹ Tesco	113,677 24,620,532	56,283	0.00 3.59
Time out	23,695,818	8,294	0.53
Whitbread	604,888	18,328	1.17
Support Services 0.50% (31.3.19 - 0.00%) Redde Northgate	5,632,528	7,829	0.50
Telecommunications 1.89% (31.3.19 - 2.57%) BT	25,116,141	29,612	1.89
Utilities 3.39% (31.3.19 - 1.50%)			
Drax	11,032,918	16,958	1.08
National Grid	681,081	6,444	0.41
SSE	2,278,123	29,707	1.90
Financials 34.80% (31.3.19 - 43.42%)			
A J Bell	9,066,765	28,107	1.79
Allied Minds	14,169,868	3,649	0.23
Aviva Beazley	9,633,334 6,699,365	25,856 26,128	1.65 1.67
Biopharma Credit	36,511,832	25,913	1.65
British Land	8,593,178	28,890	1.84
Burford Capital	4,865,974	20,359	1.30
Cambridge Innovation Capital ¹	4,344,506	3,845	0.24
Crystal Amber Fund	6,932,423	4,021	0.26
Derwent London Draper Esprit	1,477,228 4,101,943	48,276 14,439	3.08 0.92
Eurovestech ¹	38,819,368	1,390	0.92
Hiscox	2,065,963	19,110	1.22
IP	47,595,205	23,798	1.52
Lancashire	5,035,455	31,170	1.99
Land Securities	1,776,039	9,878	0.63
Legal & General	24,468,502	47,420	3.02
Marwyn Value Investors NewRiver REIT	6,484,199 12,513,673	4,733 7,471	0.30 0.48
Ombu 'D' pref. ¹	43,816	2,140	0.40
Ombu pref. ¹	223,482	12,452	0.79
Ombu ¹	1,056,081	, -	0.00
Pollen Street Secured Lending	5,233,818	36,532	2.33
Provident Financial	8,735,818	18,939	1.21
PRS REIT	27,966,274	20,695	1.32
Raven Property Raven Property 6.5% pref.	52,104,597 5,877,193	16,465 4,114	1.05 0.26
Raven property pref.	14,897,481	13,408	0.25
Royal Bank of Scotland	21,748,351	24,554	1.57
Safe Harbour	2,361,111	3,069	0.20
Secure Income REIT	5,864,920	18,826	1.20
Wilmcote	4,062,500	81	0.00
Technology 0.21% (31.3.19 - 0.35%) Mercia Technologies	21,304,997	3,238	0.21
Mercia recimologies	21,304,991	3,230	0.21
United States 8.03% (31.3.19 - 4.88%)			
Basic Materials 0.00% (31.3.19 - 0.01%) Xyleco 'A' ¹	18,038,631	_	0.00
Xyleco 'B' ¹	6,012,877	-	0.00
Health Care 7.38% (31.3.19 - 4.29%)			
Evofem Biosciences	4,148,940	17,935	1.14
Gelesis Income Series 21	869,031	6,926	0.44
Gelesis Income Series 3 ¹ Immunoscience ¹	212,836	2,974	0.19 0.00
IIIIIIIIIIIOSCIETICE-	8,016,712	-	0.00

Investment report for the year

Portfolio Statement (Unaudited) continued as at 31 March 2020	Holding or nominal value of	Market value	Percentage of total net assets
Investment	positions	£′000	%
Health Care continued			
Oxford Immunotec	2,091,285	15,517	0.99
PureTech Health	25,161,171	60,387	3.85
Vedanta Biosciences ¹	485,651	8,243	0.53
Vedanta Biosciences 'C' pref. ¹	220,751	3,747	0.24
Financials 0.40% (31.3.19 - 0.46%)			
Eight Africa Fund 'A' 1	21,649,470	6,242	0.40
Technology 0.25% (31.3.19 - 0.12%)			
Spin Transfer Technologies ¹	1,864,286	3,982	0.25
Portfolio of investments (31.3.19 - 100.09%)		1,577,257	100.59
Net other liabilities (31.3.19 - (0.09%))		(9,271)	(0.59)
Net assets		1,567,986	100.00

Unless otherwise stated, all holdings are on an official stock exchange listing or are permitted collective investment schemes.

Unquoted securities - for the year ended 31 March 2020 these amount to 7.76%
 (31 March 2019 - 4.95%) of the Net Asset Value of the Fund.

Portfolio Statement Breakdown as at 31 March 2020	Market value 31.3.20 £'000	Percentage of total net assets 31.3.20 %	Market value 31.3.19 £'000	Percentage of total net assets 31.3.19 %
Quoted securities	1,455,641	92.83	3,061,620	95.14
Unquoted securities	121,616	7.76	159,345	4.95
Portfolio of investments	1,577,257	100.59	3,220,965	100.09 (0.09)
Net other liabilities	(9,271)	(0.59)	(2,783)	
Net assets	1,567,986	100.00	3,218,182	100.00

Invesco Income Fund (UK)
Investment report for the year

Summary of Material Portfolio Changes for the year 1 April 2019 to 31 March 2020	Cost
	2000
Total purchases Largest purchases:	448,382
Denmark	
Novo Nordisk 'B'	35,469
France	
Total	44,001
Guernsey Hipgnosis Songs Fund	8,575
Switzerland	
Novartis	29,621
United Kingdom	24.250
SSE International Consolidated Airlines (UK Regd.)	34,358 31,852
Royal Dutch Shell 'B' (UK Regd.)	28,037
Amigo	26,205
Whitbread	24,229
Countryside Properties	22,764
Royal Bank of Scotland British American Tobacco	20,159
Land Securities	17,557 16,064
Tesco	14,569
infirst Pref.	11,804
BP	8,330
Time out	8,230
Aviva	7,698
National Grid Wilmcote	6,239 4,634
Timhoote	.,,65 .
	Proceeds £'000
Total sales	1,266,973
Largest sales:	
United Kingdom	
AJ Bell	124,472
BCA Marketplace	92,008
Summit Germany Imperial Brands	56,347 55,525
BTG	53,260
Royal Dutch Shell 'A' (UK Regd.)	47,728
Derwent London	44,213
Honeycomb Investment Trust	37,802
Next	37,458
Cranswick HomeServe	34,885 32,377
British American Tobacco	28,649
Talk Talk Telecom	24,065
Breedon	23,698
IP	23,658
Biopharma Credit	22,250
Aviva Tesco	21,787 21,559
Secure Income REIT	21,559
United States	
Alkermes	22,811
	, -

Financial statements

Statement of Total Return for the year 1 April 2019 to 31 March 2020	Notes	£'000	01.4.19 to 31.3.20 £'000	£'000	01.4.18 to 31.3.19 £'000
Income					
Net capital (losses)/gains	2		(821,144)		12,589
Revenue	3	100,634		138,769	
Expenses	4	(37,250)		(52,199)	
Interest payable and similar charges	5	(24)		(54)	
Net revenue before taxation		63,360		86,516	
Taxation	6	(1,298)		(817)	
Net revenue after taxation			62,062		85,699
Total return before distributions			(759,082)		98,288
Distributions	7		(97,723)		(136,125)
Change in net assets attributable to					
Shareholders from investment activities			(856,805)		(37,837)

Statement of Change in Net Assets Attributable to Shareholders for the year 1 April 2019 to 31 March 2020	£'000	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000 £'000
Opening net assets attributable to Shareholders		3,218,182	4,312,067
Amounts received on issue of shares Amounts paid on redemption of shares	16,391 (877,918)	(1	17,046 .,165,248)
		(861,527)	(1,148,202)
Dilution adjustment Change in net assets attributable to		3,658	4,854
Shareholders from investment activities		(856,805)	(37,837)
Retained distribution on accumulation shares		64,432	87,247
			53
Unclaimed distribution monies Closing net assets attributable to Shareholders		46 1,567,986	3,218,

Financial statements

Balance Sheet as at 31 March 2020	Notes	31.3.2 £'000 £'00	
Assets			
Fixed assets			
Investments		1,577,25	7 3,220,965
Current assets			
Debtors	8	35,730	12,236
Cash and bank balances	9	374	13,667
Total other assets		36,10	4 25,903
Total assets		1,613,36	1 3,246,868
Liabilities			
Investment liabilities			-
Creditors			
Bank overdrafts		1,324	_
Distribution payable		10,087	15,356
Other creditors	10	33,964	13,330
Total other liabilities		45,37	5 28,686
Total liabilities		45,37	5 28,686
Net assets attributable to Shareholders		1,567,98	6 3,218,182

Notes to the financial statements

Payable to the Manager, associates of the Manager

and agents of either of them: Fund Management Fee¹

Total expenses

Refer to pages 06 to 15 for notes applicable to the financial statements of all Funds.

1 Accounting Policies

The Fund's Accounting Policies, Distribution Policies and Generic Risk Factors are set out on pages 06 to 13.

37,250

37,250

37,250

52,199 52,199

52,199

01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
(317)	(52)
114	-
(820,941)	12,641
(821,144)	12,589
01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
32	12
6,652	12,873
202	211
16,150	16,068
4,840	2,632
63,734	97,874
9,024	9,099
100,634	138,769
01.4.19 to 31.3.20	01.4.18 to 31.3.19
	01.4.19 to 31.3.20 £'000 (317) 114 (820,941) (821,144) 01.4.19 to 31.3.20 £'000 32 6,652 202 16,150 4,840 63,734 9,024 100,634

Total audit fees of £35,300 (2019 - £34,860) exclusive of VAT payable to the auditors for the year ended 31 March 2020 are borne out of the Fund Management Fee.

Notes to the financial statements

5	Interest payable and similar charges	01.4.19	01.4.18
		₹0.31.3.20	to 31.3.19
		£′000	£′000
Inte	erest	24	54

6 Taxation	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
a) Analysis of charge for the year		
Overseas tax	1,298	817
Total tax charge	1,298	817

There is no corporation tax charge for the year (2019 - Nil).

b) Factors affecting the tax charge for the year

The tax assessed for the year is lower (2019 - lower) than the standard rate of corporation tax in the UK for an authorised investment company with variable capital. The differences are explained below:

	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Net revenue before taxation	63,360	86,516
Corporation tax at 20% (2019 -20%)	12,672	17,303
Effects of: Movement in excess expenses Overseas tax Prior year adjustment Relief on overseas tax expensed Revenue not subject to tax	3,383 1,298 (22) (56) (15,977)	5,505 817 (19) - (22,789)
Total tax charge	1,298	817

Authorised investment companies with variable capital are exempt from tax on capital gains. Therefore any capital return is not included in the above reconciliation.

c) Deferred tax

At the year end the Fund had surplus management expenses of £1,279,555,000 (2019 - £1,262,641,000). It is unlikely that the Fund will generate sufficient taxable profits in the future to utilise these expenses and therefore a deferred tax asset of £255,911,000 (2019 - £252,528,000) has not been recognised.

7 Distributions	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Accumulations and distributions paid 30 November 2019 Accumulations and distributions payable 31 May 2020	55,626 35,269	76,061 50,614
Amounts deducted on redemption of shares Amounts received on issue of shares	90,895 8,555 (1,727)	126,675 11,378 (1,928)
	97,723	136,125
The distributable amount has been calculated as follows: Net revenue after taxation Fund Management Fee taken to capital Tax relief on expenses taken to capital Equalisation on conversions	62,062 37,250 (1,513) (76)	85,699 52,199 (1,771) (2)
	97,723	136,125

Notes to the financial statements

8 Debtors	31.3.20 £'000	31.3.19 £'000
Accrued revenue	3,199	6,242
Amounts receivable for issue of shares	18	-
Foreign currency contracts awaiting settlement	304	-
Overseas tax recoverable	869	590
Sales awaiting settlement	31,340	5,404
	35,730	12,236

9 Cash and bank balances	31.3.20 £′000	31.3.19 £'000
Cash and bank balances	374	13,667

10 Other creditors	31.3.20 £′000	31.3.19 £'000
Accrued expenses	2,074	3,783
Amounts payable for redemption of shares	4,230	9,527
Foreign currency contracts awaiting settlement	302	_
Purchases awaiting settlement	27,358	20
	33,964	13,330

11 Commitments, contingent liabilities and contingent assets

There were no commitments, contingent liabilities or contingent assets at the balance sheet date (2019 - Nil).

12 Related parties

Related party interests in the Fund are disclosed in note 10 of the notes applicable to the financial statements of all Funds on page 14. Amounts payable to Invesco Fund Managers Limited in respect of Fund Management Fees are disclosed in note 4. Amounts due at the end of the accounting year for Fund Management Fees of £2,074,000 (2019 - £3,783,000) are disclosed in note 10 within accrued expenses.

13 Generic Risk factors

As one of the key objectives of the Fund is to provide income, the Manager's ongoing charge is taken from capital rather than income. This can erode capital and reduce the potential for capital growth.

The Fund may invest in private and unlisted equities which may involve additional risks such as lack of liquidity, lack of pricing transparency, less readily available information on the company and concentrated ownership. These investments may result in greater fluctuations of the value of the Fund. The Manager, however, will ensure that any investments in private and unlisted equities do not materially alter the overall risk profile of the Fund.

The Fund may use derivatives (complex instruments) in an attempt to reduce the overall risk of their investments, reduce the costs of investing and/or generate additional capital or income, although this may not be achieved. The use of such complex instruments may result in greater fluctuations of the value of the Fund. The Manager, however, will ensure that the use of derivatives within the Fund does not materially alter the overall risk profile of the Fund.

The risk factors relating to the Fund are discussed more fully in note 5 of the notes applicable to the financial statements of all Funds on pages 10 to 13.

a) Counterparty risk

The Fund was not exposed to any counterparty risk as at the balance sheet date (2019 - Nil).

Notes to the financial statements

13 Generic Risk factors continued

b) Valuation of financial instruments

The categorisation of financial instruments in the tables below reflect the basis of valuation of instruments used to measure their fair value.

	Assets £'000	Liabilities £'000
31.3.20		
Level 1: Quoted prices	1,455,641	-
Level 2: Observable market data	-	-
Level 3: Unobservable data	121,616	-
	1,577,257	-
31.3.19		
Level 1: Quoted prices	3,061,620	-
Level 2: Observable market data	-	-
Level 3: Unobservable data	159,345	-
	3,220,965	_

The majority of financial instruments are classified as level 1: Quoted prices. Instruments classified as level 3: Unobservable data mainly comprise non-market traded and unquoted securities.

Generally for the non-market traded and unquoted securities, where there is no price source from an active market for an investment, the Manager has applied judgement in determining the fair value. The Manager has used several valuation methodologies as prescribed in the International Private Equity and Venture Capital valuation guidelines to arrive at their best estimate of fair value. Valuation techniques used by the Manager are set out in Accounting Policies note 1 (i). The fair value is established by using measures of value such as:

- Price of recent transactions Management determine the fair value based on the price of recent transactions made by management or a third party.
- Milestone analysis Management assess the investment company's progress against milestones expected
 at the time of investment in order to determine whether an adjustment is required to the transaction price
 to determine fair value.
- Multiples Earnings or Revenue multiples are selected from comparable public companies based on geographic location, industry, size, risk profile, earnings growth prospects, target markets and other factors that management consider reasonable. A discount for lack of liquidity may then be applied to represent the adjustment to comparable company multiples to reflect the illiquidity of the portfolio companies relative to the comparable peer group. Management determines the discount for lack of liquidity based on its judgement, after considering market liquidity conditions and company specific factors such as the development stage of the portfolio company. One of the most common forms of multiples used for cash generating companies are EV/EBITDA multiples as EBITDA is generally seen to represent a good proxy for free cash flow. These are applied where appropriate based on the development of underlying portfolio companies but other multiples such as EV/Revenue may also be considered.
- Net assets Management determine the fair value based on the net asset value of the underlying portfolio company.

In applying the above valuation techniques in arriving at the fair value the Manager has assessed any further information available from internal and external sources to arrive at an estimated fair value, which includes but is not limited to the following:

- Reference to listed securities of the same company.
- Consideration of seniority of the securities held and terms of repayment upon realisation.
- Consideration of any trading restrictions on the investment company's shares that would limit Invesco's ability to realise its holding.
- Consideration of any outstanding payments to be made by Invesco.
- Industry statistics or events (such as mergers and acquisitions).

Notes to the financial statements

14 Portfolio transaction costs for the year 1 April 2019 to 31 March 2020

Purchases (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments Collective investment schemes	438,192 8,576	204 -	0.05 -	1,410 -	0.32
Total purchases	446,768	204		1,410	
Total purchases including transaction costs	448,382				
Sales (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments Collective investment schemes	1,158,059 110,353	565 100	0.05 0.09	774 -	0.07
Total sales	1,268,412	665		774	
Total sales net of transaction costs	1,266,973				
Derivative transaction costs		-		-	
Total transaction costs		869	869 2,184		
Total transaction costs as a % of average net assets		0.03%		0.08%	

Notes to the financial statements

14 Portfolio transaction costs continued

for the year 1 April 2018 to 31 March 2019

Purchases (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	344,250	138	0.04	880	0.26
Collective investment schemes	20,880	-	-	4	0.02
Total purchases	365,130	138		884	
Total purchases including transaction costs	366,152				
Sales (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	1,441,783	884	0.06	1,117	0.08
Collective investment schemes	25,156	17	0.07	_	-
Total sales	1,466,939	901		1,117	
Total sales net of					
transaction costs	1,464,921				
Derivative transaction costs		-		-	
Total transaction costs		1,039	1,039 2,001		
Total transaction costs as a % of average net assets		0.03%		0.05%	

The above analysis covers any direct transaction costs suffered by the Fund during the year. However it is important to understand the nature of other transaction costs associated with different investment asset classes and instruments types.

Separately identifiable direct transaction costs (commissions and taxes etc.) are attributable to the Fund's purchase and sale of equity shares. Additionally for equity shares, there is a dealing spread cost (the difference between the buying and selling prices) which will be suffered on purchase and sale transactions.

For the Fund's investment transactions in debt and money market instruments any applicable transaction charges form part of the dealing spread for these instruments. Transactions in money market instruments, cash and short-term collective investment schemes utilised as part of a daily sweep to manage the Fund's daily liquidity position are excluded from the analysis.

For the Fund's investment in collective investment scheme holdings there will potentially be dealing spread costs applicable to purchases and sales. However, additionally there are indirect transaction costs suffered in those underlying Funds, throughout the holding period for the instruments, which are not separately identifiable and do not form part of the analysis above.

Dealing spread costs suffered by the Fund vary considerably for the different asset/instrument types depending on a number of factors including transaction value and market sentiment.

At the balance sheet date the average portfolio dealing spread (difference between bid and offer prices of all investments expressed as a percentage of the offer price value) was 0.96% (2019 - 0.70%).

Notes to the financial statements

15 Share movement for the year 1 April 2019 to 31 March 2020

	Accumulation shares	Accumulation shares (No Trail)	Z Accumulation shares	Y Accumulation shares
Opening shares	43,842,078	53,786,968	92,023,288	198,551,883
Shares issued	20,691	15,339	117,317	-
Shares redeemed	(9,201,252)	(26,055,807)	(26,864,507)	(79,807,655)
Shares converted	(3,074,415)	46,887,105	3,438,932	1,356,236
Closing shares	31,587,102	74,633,605	68,715,030	120,100,464
	Income shares	Income shares (No Trail)	Z Income shares	Y Income shares
Opening shares	32,423,581	16,396,607	71,298,264	128,580,397

	Income shares	Income shares (No Trail)	Z Income shares	Y Income shares
Opening shares	32,423,581	16,396,607	71,298,264	128,580,397
Shares issued	1,044,479	19,992	4,811	163,074
Shares redeemed	(6,290,177)	(7,219,187)	(39,331,413)	(53,053,732)
Shares converted	(3,224,265)	40,262,592	1,439,151	81,993
Closing shares	23,953,618	49,460,004	33,410,813	75,771,732

16 Post balance sheet events
The Fund's post balance sheet events are set out on page 15.

Distribution tables

Distribution tables for the year 1 April 2019 to 31 March 2020

Distribution paid 30 November 2019	Net revenue pence per share	Equalisation pence per share	Net distribution paid 30.11.19 pence per share	Net distribution paid 30.11.18 pence per share
Accumulation shares Group 1 Group 2	62.3831 31.7959	- 30.5872	62.3831 62.3831	65.1674 65.1674
Accumulation shares (No Trail) Group 1 Group 2	3.4947 2.2455	- 1.2492	3.4947 3.4947	3.6328 3.6328
Z Accumulation shares Group 1 Group 2	6.1895 3.3111	- 2.8784	6.1895 6.1895	6.4241 6.4241
Y Accumulation shares Group 1 Group 2	4.6976 2.7138	- 1.9838	4.6976 4.6976	4.8740 4.8740
Income shares Group 1 Group 2	30.8570 16.7947	- 14.0623	30.8570 30.8570	33.3931 33.3931
Income shares (No Trail) Group 1 Group 2	2.2758 1.3846	- 0.8912	2.2758 2.2758	2.4505 2.4505
Z Income shares Group 1 Group 2	5.0013 2.5917	- 2.4096	5.0013 5.0013	5.3767 5.3767
Y Income shares Group 1 Group 2	3.9269 2.3049	1.6220	3.9269 3.9269	4.2208 4.2208

Group 1: shares purchased prior to 1 April 2019 Group 2: shares purchased on or after 1 April 2019

Invesco Income Fund (UK)

Distribution tables

Distribution tables continued for the year 1 April 2019 to 31 March 2020

Distribution payable 31 May 2020	Net revenue pence per share	Equalisation pence per share	Net distribution payable 31.5.20 pence per share	Net distribution paid 31.5.19 pence per share
Accumulation shares				
Group 1 Group 2	48.7034 17.1819	31.5215	48.7034 48.7034	49.7927 49.7927
Accumulation shares (No Trail)				
Group 1 Group 2	2.7357 0.7183	- 2.0174	2.7357 2.7357	2.7793 2.7793
Z Accumulation shares				
Group 1 Group 2	4.8510 2.4776	2.3734	4.8510 4.8510	4.9172 4.9172
Y Accumulation shares				
Group 1 Group 2	3.6826 1.7795	- 1.9031	3.6826 3.6826	3.7309 3.7309
Income shares				
Group 1 Group 2	23.6071 16.3627	- 7.2444	23.6071 23.6071	24.9883 24.9883
Income shares (No Trail)				
Group 1 Group 2	1.7456 0.4350	1.3106	1.7456 1.7456	1.8387 1.8387
Z Income shares				
Group 1 Group 2	3.8410 1.9482	- 1.8928	3.8410 3.8410	4.0372 4.0372
Y Income shares Group 1 Group 2	3.0166 1.5297	- 1.4869	3.0166 3.0166	3.1684 3.1684

Group 1: shares purchased prior to 1 October 2019 Group 2: shares purchased on or after 1 October 2019

Equalisation applies only to shares purchased during the distribution period (Group 2). It is the average amount of revenue included in the purchase price of all Group 2 shares and is refunded to holders of these shares as a return of capital. Being capital it is not liable to income tax. Instead, it must be deducted from the cost of shares for capital gains purposes.

Investment report for the year

The Investment Objective and Policy of the Invesco UK Enhanced Index Fund (UK)

The Fund aims to achieve capital growth and outperform the FTSE All Share ex Investment Trusts Index net of fees (the "Benchmark") over a rolling 5 year period. The Fund invests at least 80% of its assets in shares or other equity related securities of companies incorporated, domiciled or carrying out the main part of their economic activity in the UK. There is no guarantee that the Fund will achieve its target and an investor may not get back the amount invested. In pursuing the Fund's investment objective, the fund manager may consider it appropriate to also invest in other transferable securities (including non UK companies), money-market instruments, collective investment schemes (including funds managed by the Invesco group), deposits and cash. The Fund may use derivatives for efficient portfolio management purposes only, to reduce risk, reduce costs and/or generate additional capital or income.

On the 7 August 2019 there was an update to the Prospectus for the various ICVC funds in light of the FCA's Asset Management Market Study. As part of this update, various changes were implemented regarding the Fund's investment objectives, investment policies, investment strategies and benchmark disclosures, all for clarification purposes only. There has been no changes to the way the Funds are managed as a result of these changes. The updated prospectus is available at www.invesco.co.uk. The investment objectives and policies currently shown within these financial statements are those that were in place as at 31 March 2020.

Performance ¹	11	-	-	Percer	ntage growth
to 31 March 2020	Since 30.9.19 %	Since 31.3.19 %	Since 31.3.17 %	Since 31.3.15 %	Since 31.3.10 %
Invesco UK Enhanced Index Fund (UK) (Z Accumulation shares) ² FTSE All-Share (ex Investment Trusts)	-23.55	-20.31	-12.35	2.42	63.14
Index TR ³	-22.49	-18.96	-13.07	1.64	51.40

Standardised rolling 12 month performance			'	Percer	ntage growth
• •	31.3.15 31.3.16 %	31.3.16 31.3.17 %	31.3.17 31.3.18 %	31.3.18 31.3.19 %	31.3.19 31.3.20 %
Invesco UK Enhanced Index Fund (UK) (Z Accumulation shares) ² FTSE All-Share (ex Investment Trusts)	-4.0	21.7	5.0	4.8	-20.3
Index TR ³	-4.0	21.8	1.0	6.2	-19.0

This standardised past performance information is updated on a quarterly basis. Should you require up to date past performance information, this is available on our website www.invesco.co.uk or by contacting us.

Fund performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. This may differ from the performance figure shown on page 39 for Z Accumulation shares as the figure above is based on the quoted 12pm price and the figure shown on page 39 is based on the close of business bid price. FTSE All-Share (ex Investment Trusts) Index TR² data source: Lipper, total return, in Sterling.

The value of investments and any income from them will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.

Past performance is not a guide to future returns. Current tax levels and reliefs may change. Depending on individual circumstances, this may affect investment returns.

Performance based on the Published Net Asset Value.

Effective 28 July 2016, the primary share class changed from Accumulation share (No Trail) class to Z Accumulation share class. Performance figures are based on the Z Accumulation share class. As this was launched on 28 July 2016, for the periods prior to this launch date, performance figures are based on the Accumulation share (No Trail) class, without any adjustment for fees.

This is a Target Benchmark. The Fund aims to outperform the Benchmark net of fees over a rolling 5 year period. The Fund has a high correlation to the Benchmark and has similar risk characteristics aiming for a tracking error target of 1.5%. As a result, this will limit the extent to which the Fund's performance will deviate from the Benchmark. The Fund's performance can be measured against the Benchmark.

Investment report for the year

Strategy, review and outlook

The Fund fell in value during the year to the end of March 2020, under-performing the FTSE All-Share (ex Investment Trusts) Index TR.

Fund performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. Performance figures are based on the Z Accumulation share class. FTSE All-Share (ex Investment Trusts) Index TR data source: Lipper, total return, in Sterling.

Past performance is not a guide to future returns.

UK equity markets ended the one-year period until March 2020 in deep negative territory. Despite continued fears of a trade war between the US and China over the whole first half of the year 2019, UK equity markets were able to deliver positive returns for the second quarter 2019. From a political perspective, Brexit headlines and uncertainties dominated markets in the third quarter of 2019 which lead to only marginal positive returns. Although starting with a negative October into the fourth quarter 2019, as investors saw a worse than expected PMI for the UK's services sector, the overall markets rose steadily in subsequent weeks, capping off a year of strong returns in 2019. Especially news of an emphatic victory for the UK's Conservative Party in mid-December, boosted by the prospect of an end to the political impasse and a period of stability, drove investors sentiment. The first quarter 2020 was dominated by heavy selloffs around the globe. Investors fear of a widespread of the novel corona virus outside of China lead to a significant plunge in equity markets at a speed never seen before. Although stocks rallied towards the end of the quarter as governments around the world launched unprecedented stimulus measures while central banks cut interest rates to support economic activity in the months ahead, UK equity markets provided a substantial negative return in the first quarter of 2020.

The Fund's performance is generated through a quantitative bottom-up multi-factor investment process based on four factors: Earnings Momentum, Price Momentum, Quality and Value. Relative risk is controlled with the help of an optimiser, an analysis tool that recommends trades to maximise portfolio exposure to the selected stocks within predetermined risk/return parameters. In terms of portfolio construction, we tightly constrain the risk taken in sectors and industries.

Over the one-year period until March 2020, our multi-factor model posted negative contributions to active return. Whilst our Quality factor was able to contribute positively, all other factors Earnings and Price Momentum as well as Value detracted. Here, Value weighed most on active return. In terms of individual stock performance, underweighted positions relative to the benchmark in Glencore, Royal Dutch Shell and Rolls Royce contributed positively. Conversely, overweights in BHP, Evraz and Lloyds Banking detracted most from active return.

Regarding changes in the portfolio, we recently increased our position in AstraZeneca, as the company has an attractive Quality score. Furthermore, we increased our positions in Tesco and HSBC for diversification reasons in the portfolio. On the other hand, we decreased our holdings in GlaxoSmithKline due to negative Earnings Momentum and Quality scores. We also decreased our positions in Smith & Nephew due to an overall negative factor-score. A decline of the Quality score resulted in a partial sale of our Barratt Developments position.

Our diversified and disciplined approach to stock selection favours companies that, in our view, are attractively valued, have good earnings and price momentum and have management acting in the interest of shareholders. We believe that we can add value through the systematic application of fundamental and behavioural insights. Disciplined portfolio construction and cost-effective trading are integral to our investment process, which we believe should help us preserve value added from stock selection and reduce the probability of significant underperformance.

Michael Fraikin and Alexander Uhlmann, Fund Managers

Where Michael Fraikin and Alexander Uhlmann have expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.

The Fund's ten largest investments are	%
Royal Dutch Shell	6.16
AstraZeneca	5.10
GlaxoSmithKline	4.86
HSBC	4.80
British American Tobacco	3.61
BP	3.32
Rio Tinto	3.22
Diageo	2.88
Unilever	2.83
BHP	2.46

Investment report for the year

Comparative tables			
Year ended Accumulation shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share	•		
Opening net asset value per share	524.58	497.90	477.70
Return before operating charges*	(103.66)	27.98	21.45
Operating charges	(1.34)	(1.30)	(1.25)
Return after operating charges	(105.00)	26.68	20.20
Distributions	(22.18)	(22.67)	(19.16)
Retained distributions on accumulation shares	22.18	22.67	19.16
Closing net asset value per share	419.58	524.58	497.90
olosing het asset value per share	417.50	324.50	471.70
*After direct transaction costs of	(1.37)	(1.73)	(4.48)
Performance	(00.000)		
Return after charges	(20.02%)	5.36%	4.23%
Other information			
Closing net asset value (£'000)	200,755	208,856	142,364
Closing number of shares	47,846,644	39,814,075	28,592,748
Operating charges	0.25%	0.25%	0.25%
Direct transaction costs Performance fee	0.26%	0.33%	0.89%
			_
Prices	F04.10	F(2,42	F2F 16
Highest share price Lowest share price	584.19 364.15	562.43 475.97	535.16 469.82
· ·			
Year ended Z Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Z Accumulation shares Change in net assets per share	(pence per share)	(pence per share)	(pence per share)
Z Accumulation shares Change in net assets per share Opening net asset value per share	(pence per share)	(pence per share) 231.69	(pence per share) 222.25
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges*	(pence per share) 244.13 (48.24)	(pence per share) 231.69 13.02	(pence per share) 222.25 10.00
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges	(pence per share) 244.13 (48.24) (0.60)	(pence per share) 231.69 13.02 (0.58)	(pence per share) 222.25 10.00 (0.56)
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges	(pence per share) 244.13 (48.24) (0.60) (48.84)	(pence per share) 231.69 13.02 (0.58) 12.44	222.25 10.00 (0.56) 9.44
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions	(pence per share) 244.13 (48.24) (0.60)	(pence per share) 231.69 13.02 (0.58)	(pence per share) 222.25 10.00 (0.56)
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35)	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58)	222.25 10.00 (0.56) 9.44 (8.96)
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions	(pence per share) 244.13 (48.24) (0.60) (48.84)	(pence per share) 231.69 13.02 (0.58) 12.44	222.25 10.00 (0.56) 9.44
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35)	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96
Z Accumulation shares Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64)	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81)	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08)
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000)	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64)	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81)	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08)
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64)	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37%	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25% 108,430 46,799,626
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares Operating charges	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64) (20.01%) 219,719 112,510,060 0.24%	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37% 208,080 85,234,219 0.24%	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25% 108,430 46,799,626 0.24%
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares Operating charges Direct transaction costs	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64) (20.01%) 219,719 112,510,060	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37% 208,080 85,234,219	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25% 108,430 46,799,626 0.24%
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares Operating charges Direct transaction costs Performance fee	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64) (20.01%) 219,719 112,510,060 0.24%	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37% 208,080 85,234,219 0.24%	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25%
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares Operating charges Direct transaction costs Performance fee Prices	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64) (20.01%) 219,719 112,510,060 0.24% 0.26% -	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37% 208,080 85,234,219 0.24% 0.33% -	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25% 108,430 46,799,626 0.24% 0.89% -
Change in net assets per share Opening net asset value per share Return before operating charges* Operating charges Return after operating charges Distributions Retained distributions on accumulation shares Closing net asset value per share *After direct transaction costs of Performance Return after charges Other information Closing net asset value (£'000) Closing number of shares Operating charges Direct transaction costs Performance fee	(pence per share) 244.13 (48.24) (0.60) (48.84) (10.35) 10.35 195.29 (0.64) (20.01%) 219,719 112,510,060 0.24%	(pence per share) 231.69 13.02 (0.58) 12.44 (10.58) 10.58 244.13 (0.81) 5.37% 208,080 85,234,219 0.24%	(pence per share) 222.25 10.00 (0.56) 9.44 (8.96) 8.96 231.69 (2.08) 4.25% 108,430 46,799,626 0.24%

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued			
Year ended Y Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	244.19	231.73	222.27
Return before operating charges*	(48.26)	13.02	10.00
Operating charges	(0.57)	(0.56)	(0.54)
Return after operating charges	(48.83)	12.46	9.46
Distributions	(10.38)	(10.60)	(8.96)
Retained distributions on accumulation shares	10.38	10.60	8.96
Closing net asset value per share	195.36	244.19	231.73
·		(0.04)	
*After direct transaction costs of Performance	(0.64)	(0.81)	(2.09)
Return after charges	(20.00%)	5.38%	4.26%
Other information	(20.0070)	J.3070	4,2070
Closing net asset value (£'000)	49,270	35,926	13,299
Closing number of shares	25,219,549	14,712,298	5,739,048
Operating charges	0.23%	0.23%	0.23%
Direct transaction costs	0.26%	0.33%	0.89%
Performance fee	-	_	_
Prices			
Highest share price	271.99	261.77	249.06
Lowest share price	169.55	221.55	218.61
Year ended Income shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share	•••••	•	
Opening net asset value per share	286.25	283.63	282.84
Return before operating charges*	(54.89)	16.13	12.76
Operating charges	(0.72)	(0.73)	(0.73)
Return after operating charges	(55.61)	15.40	12.03
Distributions	(11.99)	(12.78)	(11.24)
Retained distributions on accumulation shares		_	_
Closing net asset value per share	218.65	286.25	283.63
*After direct transaction costs of Performance	(0.74)	(0.97)	(2.62)
Return after charges	(19.43%)	5.43%	4.25%
Other information	(
Closing net asset value (£'000)	24,538	29,099	38,561
Closing number of shares	11,222,577	10,165,537	13,595,696
Operating charges	0.25%	0.25%	0.25%
Direct transaction costs	0.26%	0.33%	0.89%
Performance fee	-	-	-
Prices			
Highest share price	310.97	320.38	309.84
Lowest share price	193.84	264.73	278.18

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued			
Year ended Z Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share	-		
Opening net asset value per share	217.36	215.38	214.78
Return before operating charges*	(41.69)	12.25	9.70
Operating charges	(0.52)	(0.54)	(0.53)
Return after operating charges Distributions	(42.21)	11.71	9.17
Retained distributions on	(9.12)	(9.73)	(8.57)
accumulation shares	_	_	_
Closing net asset value per share	166.03	217.36	215.38
*After direct transaction costs of	(0.56)	(0.74)	(1.99)
Performance		•••••	
Return after charges	(19.42%)	5.44%	4.27%
Other information			
Closing net asset value (£'000)	12,241	11,150	6,094
Closing number of shares	7,372,385	5,129,594	2,829,397
Operating charges	0.24%	0.24%	0.24%
Direct transaction costs Performance fee	0.26%	0.33%	0.89%
Prices			
Highest share price	236.14	243.29	235.29
Lowest share price	147.20	201.03	211.24
Year ended Y Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	217.36	215.37	214.78
Return before operating charges*	(41.68)	12.26	9.68
Operating charges	(0.50)	(0.51)	(0.51)
Return after operating charges	(42.18)	11.75	9.17
Distributions	(9.15)	(9.76)	(8.58)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	166.03	217.36	215.37
*After direct transaction costs of	(0.56)	(0.74)	(1.99)
Performance		•••••	
Return after charges	(19.41%)	5.46%	4.27%
Other information			
Closing net asset value (£'000)	1,961	2,364	214
Closing number of shares	1,181,084	1,087,528	99,444
Operating charges	0.23%	0.23%	0.23%
Direct transaction costs Performance fee	0.26%	0.33%	0.89%
Prices			
Highest share price	236.15	243.29	235.29
Lowest share price	147.21	201.03	211.24

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Portfolio Statement (Unaudited) as at 31 March 2020	Holding or nominal	Market	Percentage of total
Investment	value of positions	value £'000	net assets %
Georgia 0.06% (31.3.19 - 0.16%)			
Financials 0.06% (31.3.19 - 0.16%) Bank of Georgia	34,325	314	0.06
Israel Nil (31.3.19 - 0.28%) Financials Nil (31.3.19 - 0.28%)			
Republic of Ireland 0.17% (31.3.19 - Nil) Consumer Goods 0.17% (31.3.19 - Nil) Greencore	507,414	837	0.17
orecined to	301,111	001	0.11
Switzerland 0.37% (31.3.19 - 0.85%) Basic Materials 0.06% (31.3.19 - 0.15%) Glencore	256,155	317	0.06
Industrials 0.16% (31.3.19 - Nil)			
IWG	462,835	798	0.16
Consumer Goods 0.15% (31.3.19 - 0.70%) Coca-Cola HBC	42.489	738	0.15
Coca Cola Fibe	42,407	750	0.13
United Kingdom 95.39% (31.3.19 - 94.20%) Oil & Gas 9.71% (31.3.19 - 14.82%)			
BP	4,920,704	16,900	3.32
Cairn Energy	486,811	377	0.07
Petrofac Premier Oil	381,824 238,017	747 41	0.15 0.01
Royal Dutch Shell 'A' (UK Regd.)	1,453,752	20,628	4.06
Royal Dutch Shell 'B' (UK Regd.)	784,634	10,668	2.10
Basic Materials 8.50% (31.3.19 - 9.59%)	500 500	7 404	
Anglo American BHP	528,583 1,000,562	7,486 12,525	1.47 2.46
Centamin	894,968	1,088	0.21
Evraz Mondi	612,841 269,299	1,419 3.719	0.28 0.73
Petropavlovsk	1,588,337	336	0.73
Rio Tinto (UK Regd.)	439,914 15.952	16,354	3.22
Victrex	15,952	314	0.06
Industrials 8.55% (31.3.19 - 6.94%)	F20.704	2.520	0.50
Aggreko Avon Rubber	520,704 11,503	2,538 265	0.50 0.05
Babcock International	220,637	844	0.17
BAE Systems Biffa	794,295 105,273	4,143 189	0.81 0.04
Bodycote	126,152	712	0.14
Chemring Diploma	118,603 93,804	237 1,513	0.05 0.30
Essentra	142,097	373	0.07
Experian	259,774	5,848	1.15
Ferguson Forterra	137,173 208,746	6,933 368	1.36 0.07
Howden Joinery	1,228,528	6,278	1.23
Ibstock Intertek	328,270 3,917	499 185	0.10 0.04
Marshalls	254,752	1,490	0.29
Meggitt Morgan Advanced Materials	526,954 53,172	1,526 98	0.30 0.02
Morgan Sindall	29,735	351	0.02
Oxford Instruments	17,997	230	0.05
PageGroup QinetiQ	274,873 259,246	1,001 834	0.20 0.16
Rentokil Initial	459,675	1,782	0.35
Travis Perkins Ultra Electronics	256,067 149,438	2,260 2,989	0.44 0.59
ord a Electronica	177,730	2,707	0.57

Portfolio Statement (Unaudited) continued	Holding or		Percentage
as at 31 March 2020	nominal value of	Market value	of total net assets
Investment	positions	£'000	%
Consumer Goods 16.43% (31.3.19 - 14.44%)	104 220	1 007	0.27
Associated British Foods	104,220	1,887	0.37 0.83
Barratt Developments Berkeley	958,496 9,005	4,227 326	0.63
British American Tobacco	666,127	18,365	3.61
Britvic	126,760	887	0.18
Cranswick	32,001	1,183	0.23
Diageo	566,595	14,647	2.88
Games Workshop	16,317	706	0.14
Imperial Brands	284,113	4,252	0.84
Persimmon	152,333	2,919	0.57
Reckitt Benckiser	162,342	9,982	1.96
Redrow	96,744	348	0.07
Tate & Lyle	1,100,516	7,204	1.42
Taylor Wimpey	1,129,713	1,327	0.26
Unilever	353,215	14,378 905	2.83 0.18
Vistry	157,323	905	0.18
Health Care 12.47% (31.3.19 - 9.23%)	250 522	25.026	F 10
AstraZeneca	359,523	25,936	5.10
ConvaTec Genus	1,104,292 6,371	2,059 207	0.41 0.04
GlaxoSmithKline		24,714	4.86
Hikma Pharmaceuticals	1,632,157 234.240	4,753	0.93
Smith & Nephew	400,057	5,735	1.13
	,	-,	
Consumer Services 11.54% (31.3.19 - 13.30%)	46.000	224	0.04
4imprint	16,902	326	0.06
Auto Trader	1,147,988	5,041	0.99
Compass Dixons Carphone	304,385 832,460	3,844 649	0.76 0.13
Domino's Pizza	83,238	235	0.13
Dunelm	321,194	2,269	0.45
FirstGroup	1,444,504	729	0.14
Frasers	122,487	223	0.04
Future	87,081	871	0.17
Greggs	127,640	2,060	0.40
Inchcape	358,533	1,553	0.31
International Consolidated Airlines (UK Regd.)	801,751	1,724	0.34
ITV	2,986,377	1,972	0.39
J Sainsbury	127,216	268	0.05
JD Sports Fashion	234,681	1,074	0.21
Marks & Spencer Moneysupermarket.com	196,767 421,487	195 1,281	0.04 0.25
Morrison (Wm.) Supermarkets	1,477,767	2,630	0.23
Next	137,026	5,580	1.10
Pets at Home	940,264	2,409	0.47
RELX	637,587	11,040	2.17
Rightmove	532,247	2,594	0.51
Stagecoach	342,306	239	0.05
Tesco	2,645,704	6,048	1.19
WH Smith	23,896	273	0.05
William Hill	664,780	453	0.09
WPP	561,350	3,094	0.61
Telecommunications 2.58% (31.3.19 - 2.60%)			
BT Electronic Electron	1,633,491	1,926	0.38
Telecom Plus	25,120	311	0.06
Vodafone	9,620,519	10,869	2.14
Utilities 3.88% (31.3.19 - 2.28%)			
Centrica (31.3.19 - 2.20%)	1,421,706	541	0.11
Drax	764,950	1,176	0.23
Halma	84,841	1,630	0.32
National Grid	888,783	8,410	1.66
Severn Trent	51,471	1,173	0.23
SSE	370,975	4,838	0.95
United Utilities	215,381	1,944	0.38

Portfolio Statement (Unaudited) continued as at 31 March 2020	Holding or nominal	Market	Percentage of total
Investment	value of positions	value £'000	net assets %
Financials 19.33% (31.3.19 - 19.17%)	positions		
3i	842,965	6,678	1.31
Admiral	21,668	483	0.10
Ashmore	778,516	2,775	0.10
Aviva	1,373,563	3,687	0.33
Barclays	3,399,921	3,200	0.73
British Land	191,572	5,200 644	0.03
Derwent London	4,936	161	0.13
Direct Line	4,936 64,557	191	0.03
	408,358	316	0.04
Hammerson			
HSBC (UK Regd.)	5,373,993	24,411	4.80
IG	51,726	357	0.07
IMI	92,256	690	0.14
Intermediate Capital	345,813	3,099	0.61
Investec	152,020	230	0.05
John Laing	52,477	177	0.03
Jupiter Fund Management	467,982	936	0.18
Land Securities	104,682	582	0.11
Legal & General	3,489,022	6,762	1.33
Lloyds Banking	28,805,463	9,216	1.81
London Stock Exchange	87,091	6,333	1.25
M&G	608,119	685	0.13
Man	1,692,484	2,106	0.41
OneSavings Bank	260,328	652	0.13
Paragon	323,946	1,075	0.21
Phoenix	224,395	1,406	0.28
Prudential	941,369	9,715	1.91
Quilter	144,047	170	0.03
Rathbone Brothers	10,422	156	0.03
Royal Bank of Scotland	131,403	148	0.03
Savills	84,499	697	0.14
Segro	236,209	1,805	0.35
Shaftesbury	170,026	1,049	0.21
Sirius Real Estate	463,622	306	0.06
Standard Chartered	1,052,723	4,693	0.92
Standard Life Aberdeen	995,538	2,229	0.44
TP ICAP	45,602	154	0.03
Tritax Big Box Reit	291,191	327	0.06
Technology 2.40% (31.3.19 - 1.83%)			
Avast	777,723	3,060	0.60
AVEVA	15,431	539	0.00
	134,827		0.11
Computacenter FDM	64,121	1,929 474	0.38
NCC Same	161,165	267	0.05
Sage	474,234	2,806	0.55
Softcat Spirent Communications	210,744 463,672	2,185 964	0.43 0.19
United States 0.11% (31.3.19 - 0.69%) Consumer Services 0.11% (31.3.19 - 0.69%)			
Carnival	59,266	581	0.11
Futures and Derivatives 0.20% (31.3.19 - 0.02%)			
Futures 0.20% (31.3.19 - 0.02%) FTSE 100 Index futures contracts 19/6/2020	249	1,028	0.20
		1,020	
Portfolio of investments (31.3.19 - 96.20%)		489,665	96.30
Net other assets (31.3.19 - 3.80%)		18,819	3.70
Net assets		508,484	100.00

Unless otherwise stated, all holdings are on an official stock exchange listing or are permitted collective investment schemes.

Summary of Material Portfolio Changes	
for the year 1 April 2019 to 31 March 2020	Cost £'000
Total purchases	267,981
Largest purchases:	
United Kingdom	
AstraZeneca	12,014
British American Tobacco	11,112
Diageo Compass	7,678 7,266
Royal Dutch Shell 'A' (UK Regd.)	5,185
Royal Dutch Shell 'B' (UK Regd.)	2,004
Standard Chartered	7,027
GlaxoSmithKline	6,709
National Grid	6,225
Unilever Parrett Developments	6,139 5,931
Barratt Developments HSBC (UK Regd.)	5,909
Prudential	5,499
Tesco	5,483
Sage	5,317
Rio Tinto (UK Regd.)	5,291
WPP	5,220
Ferguson BHP	5,159 5,008
Anglo American	4,785
Angle American	1,1.00
	Proceeds
Total sales	£′000
Total sales Largest sales:	
Largest sales:	£′000
	£'000 111,738
Largest sales: Switzerland Coca-Cola HBC	£′000
Largest sales: Switzerland	£'000 111,738
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson	2,410 6,549 5,140
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry	2,410 6,549 5,140 4,349
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International	2,410 6,549 5,140 4,349 3,684
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew	2,410 2,410 6,549 5,140 4,349 3,684 3,218
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG Ferguson	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234 2,228
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234 2,228 2,134
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG Ferguson Auto Trader Intertek Berkeley	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234 2,228 2,134 2,000 1,983
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG Ferguson Auto Trader Intertek Berkeley PageGroup	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234 2,228 2,134 2,000 1,983 1,935
Largest sales: Switzerland Coca-Cola HBC United Kingdom Greene King Pearson Burberry Micro Focus International Smith & Nephew Compass Evraz Grafton Hikma Pharmaceuticals Tullow Oil GlaxoSmithKline Persimmon IG Ferguson Auto Trader Intertek Berkeley	2,410 2,410 6,549 5,140 4,349 3,684 3,218 2,987 2,820 2,728 2,720 2,631 2,318 2,298 2,234 2,228 2,134 2,000 1,983

Financial statements

Statement of Total Return for the year 1 April 2019 to 31 March 2020	Notes	£'000	01.4.19 to 31.3.20 £'000	£'000	01.4.18 to 31.3.19 £'000
Income					
Net capital (losses)/gains	2		(150,206)		2,141
Revenue	3	24,592		17,526	
Expenses	4	(1,361)		(903)	
Interest payable and similar charges	5	-		(2)	
Net revenue before taxation		23,231		16,621	
Taxation	6	(271)		(209)	
Net revenue after taxation			22,960		16,412
Total return before distributions			(127,246)		18,553
Distributions	7		(22,960)		(16,412)
Change in net assets attributable to					
Shareholders from investment activities			(150,206)		2,141

Statement of Change in Net Assets Attributable	,	1		
to Shareholders for the year 1 April 2019 to 31 March 2020	£'000	01.4.19 to 31.3.20 £'000	£′000	01.4.18 to 31.3.19 £'000
Opening net assets attributable to Shareholders		495,475		308,962
Amounts received on issue of shares Amounts paid on redemption of shares	166,774 (27,018)		208,678 (41,528)	
		139,756		167,150
Dilution adjustment Change in net assets attributable to		805		951
Shareholders from investment activities Retained distribution on accumulation shares		(150,206) 22,654		2,141 16,271
Closing net assets attributable to Shareholders		508,484		495,475

Financial statements

Balance Sheet as at 31 March 2020	Notes	£′000	31.3.20 £'000	٤′000	31.3.19 £'000
Assets	•				
Fixed assets					
Investments			489,665		476,631
Current assets					
Debtors	8	3,513		8,554	
Cash and bank balances	9	18,760		11,224	
Total other assets			22,273		19,778
Total assets	•		511,938		496,409
Liabilities	-				
Investment liabilities			-		-
Creditors					
Distribution payable		833		822	
Other creditors	10	2.621		112	
Total other liabilities			3,454		934
Total liabilities	•		3,454		934
Net assets attributable to Shareholders	•		508,484		495,475

Notes to the financial statements

Refer to pages 06 to 15 for notes applicable to the financial statements of all Funds.

1 Accounting Policies

The Fund's Accounting Policies, Distribution Policies and Generic Risk Factors are set out on pages 06 to 13.

2 Net capital (losses)/gains	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Derivative securities	(6,295)	606
Foreign currency (losses)/gains	(19)	22
Non-derivative securities	(143,892)	1,513
Net capital (losses)/gains	(150,206)	2,141
3 Revenue	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Bank interest	51	41
Derivative income	693	380
Non-taxable overseas dividends	3,118	1,875
Taxable overseas dividends	125	89
UK dividends	20,427	15,040
UK REIT dividends	178	101
	24,592	17,526
4 Expenses	01.4.19 to 31.3.20	01.4.18 to 31.3.19
	£′000	2′000
Payable to the Manager, associates of the Manager and agents of either of them:		
Fund Management Fee ¹	1,361	903
	1,361	903
Total expenses	1,361	903

Total audit fees of £8,250 (2019 - £6,005) exclusive of VAT payable to the auditors for the year ended 31 March 2020 are borne out of the Fund Management Fee.

Notes to the financial statements

5	Interest payable and similar charges	01.4.19 to 31.3.20	01.4.18 to 31.3.19
		£'000	£′000
Int	erest	_	2

6 Taxation	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
a) Analysis of charge for the year		
Overseas tax	271	209
Total tax charge	271	209

There is no corporation tax charge for the year (2019 - Nil).

b) Factors affecting the tax charge for the year

The tax assessed for the year is lower (2019 - lower) than the standard rate of corporation tax in the UK for an authorised investment company with variable capital. The differences are explained below:

	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Net revenue before taxation	23,231	16,621
Corporation tax at 20% (2019 -20%)	4,646	3,324
Effects of: Movement in excess expenses Overseas tax Relief on overseas tax expensed Revenue not subject to tax	66 271 (3) (4,709)	62 209 (3) (3,383)
Total tax charge	271	209

Authorised investment companies with variable capital are exempt from tax on capital gains. Therefore any capital return is not included in the above reconciliation.

c) Deferred tax

At the year end the Fund had surplus management expenses of £3,314,000 (2019 - £2,986,000). It is unlikely that the Fund will generate sufficient taxable profits in the future to utilise these expenses and therefore a deferred tax asset of £663,000 (2019 - £597,000) has not been recognised.

7 Distributions	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Accumulations and distributions paid 30 November 2019 Accumulations and distributions payable 31 May 2020	13,884 10,732	8,876 9,402
Amounts deducted on redemption of shares Amounts received on issue of shares	24,616 223 (1,879)	18,278 368 (2,234)
	22,960	16,412
The distributable amount has been calculated as follows: Net revenue after taxation	22,960	16,412
	22,960	16,412

Notes to the financial statements

8 Debtors	31.3.20 £'000	31.3.19 £′000
Accrued revenue	2,197	3,037
Amounts receivable for issue of shares	848	5,422
Overseas tax recoverable	153	95
Sales awaiting settlement	315	-
	3,513	8,554

9 Cash and bank balances	31.3.20 £'000	31.3.19 £′000
Amounts held at futures clearing houses and brokers	319	175
Cash and bank balances	18,441	11,049
	18,760	11,224

10 Other creditors	31.3.20 £′000	31.3.19 £′000
Accrued expenses	106	100
Amounts payable for redemption of shares	1,353	12
Purchases awaiting settlement	1,162	-
	2,621	112

11 Commitments, contingent liabilities and contingent assets

There were no commitments, contingent liabilities or contingent assets at the balance sheet date (2019 - Nil).

12 Related parties

Related party interests in the Fund are disclosed in note 10 of the notes applicable to the financial statements of all Funds on page 14. Amounts payable to Invesco Fund Managers Limited in respect of Fund Management Fees are disclosed in note 4. Amounts due at the end of the accounting year for Fund Management Fees of £106,000 (2019 - £100,000) are disclosed in note 10 within accrued expenses.

13 Generic Risk factors

The Fund's performance may be adversely affected by variations in the relative strength of world currencies or if Sterling strengthens against those currencies.

The Fund may use derivatives (complex instruments) in an attempt to reduce the overall risk of their investments, reduce the costs of investing and/or generate additional capital or income, although this may not be achieved. The use of such complex instruments may result in greater fluctuations of the value of the Fund. The Manager, however, will ensure that the use of derivatives within the Fund does not materially alter the overall risk profile of the Fund.

The risk factors relating to the Fund are discussed more fully in note 5 of the notes applicable to the financial statements of all Funds on pages 10 to 13.

a) Counterparty risk

The Fund was not exposed to any counterparty risk as at the balance sheet date (2019 - Nil).

Notes to the financial statements

13 Generic Risk factors

b) Valuation of financial instruments

The categorisation of financial instruments in the tables below reflect the basis of valuation of instruments used to measure their fair value.

	Assets £'000	Liabilities £'000
31.3.20		
Level 1: Quoted prices	489,665	-
Level 2: Observable market data	-	-
Level 3: Unobservable data	-	-
	489,665	-
31.3.19		
Level 1: Quoted prices	476,631	_
Level 2: Observable market data	_	-
Level 3: Unobservable data	-	-
	476,631	-

All financial instruments are classified as level 1: Quoted prices.

14	Portfolio	transac	ction o	osts
	- 4 4	120101	2414	1 2020

for the year 1 April 2019 to 31 March 2020

Purchases (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	266,607	133	0.05	1,241	_
Total purchases	266,607	133		1,241	
Total purchases including transaction costs	267,981				
Sales (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	111,790	52	0.05	-	-
Total sales	111,790	52		-	
Total sales net of transaction costs	111,738				
Derivative transaction costs		8		-	
Total transaction costs		193		1,241	
Total transaction costs as a % of average net assets		0.04% 0.22%		0.22%	

Notes to the financial statements

14 Portfolio transaction costs continued

for the year 1 April 2018 to 31 March 2019

Purchases (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	241,428	113	0.05	1,087	0.45
Total purchases	241,428	113		1,087	
Total purchases including transaction costs	242,628				
Sales (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	63,797	25	0.04	-	-
Total sales	63,797	25		_	
Total sales net of transaction costs	63,772				
Derivative transaction costs		5		-	
Total transaction costs		143		1,087	
Total transaction costs as a % of average net assets		0.04% 0.29%			

The above analysis covers any direct transaction costs suffered by the Fund during the year. However it is important to understand the nature of other transaction costs associated with different investment asset classes and instruments types.

Separately identifiable direct transaction costs (commissions and taxes etc.) are attributable to the Fund's purchase and sale of equity shares. Additionally for equity shares, there is a dealing spread cost (the difference between the buying and selling prices) which will be suffered on purchase and sale transactions.

For the Fund's investment transactions in debt and money market instruments any applicable transaction charges form part of the dealing spread for these instruments. Transactions in money market instruments, cash and short-term collective investment schemes utilised as part of a daily sweep to manage the Fund's daily liquidity position are excluded from the analysis.

For the Fund's investment in collective investment scheme holdings there will potentially be dealing spread costs applicable to purchases and sales. However, additionally there are indirect transaction costs suffered in those underlying Funds, throughout the holding period for the instruments, which are not separately identifiable and do not form part of the analysis above.

During the year the Fund utilised derivative instruments including contract for differences, interest rate swaps, futures and options covering different underlying asset classes. The settlement values for opening and closing derivative positions are not comparable to principal values for transactions in direct holding investments and therefore purchase and sale amounts for derivative transactions are not quantified in the analysis above. Transaction costs for derivatives positions will be either suffered as direct costs or form part of the dealing spread for the instruments. Any direct costs are identified in the analysis above.

Dealing spread costs suffered by the Fund vary considerably for the different asset/instrument types depending on a number of factors including transaction value and market sentiment.

At the balance sheet date the average portfolio dealing spread (difference between bid and offer prices of all investments expressed as a percentage of the offer price value) was 0.13% (2019 - 0.05%).

Notes to the financial statements

15 Share movement for the year 1 April 2019 to 31 March 2020

	Accumulation shares (No Trail)	Z Accumulation shares	Y Accumulation shares
Opening shares	39,814,075	85,234,219	14,712,298
Shares issued Shares redeemed Shares converted	11,160,888 (3,123,154) (5,165)	29,453,937 (2,253,205) 75,109	11,507,124 (935,885) (63,988)
Closing shares	47,846,644	112,510,060	25,219,549
	Income shares (No Trail)	Z Income shares	Y Income shares
Opening shares	10,165,537	5,129,594	1,087,528
Shares issued Shares redeemed Shares converted	1,414,293 (357,253) -	2,586,428 (343,637) -	602,264 (508,708)
Closing shares	11,222,577	7,372,385	1,181,084

16 Post balance sheet events

The Fund's post balance sheet events are set out on page 15.

Distribution tables

Distribution tables for the year 1 April 2019 to 31 March 2020

Distribution paid 30 November 2019	Net revenue pence per share	Equalisation pence per share	Net distribution paid 30.11.19 pence per share	Net distribution paid 30.11.18 pence per share
Accumulation shares (No Trail) Group 1 Group 2	13.3564 8.0748	- 5.2816	13.3564 13.3564	12.7516 12.7516
Z Accumulation shares Group 1 Group 2	6.2288 3.0875	- 3.1413	6.2288 6.2288	5.9467 5.9467
Y Accumulation shares Group 1 Group 2	6.2433 3.3476	- 2.8957	6.2433 6.2433	5.9607 5.9607
Income shares (No Trail) Group 1 Group 2	7.2889 1.0118	- 6.2771	7.2889 7.2889	7.2638 7.2638
Z Income shares Group 1 Group 2	5.5466 2.7361	- 2.8105	5.5466 5.5466	5.5284 5.5284
Y Income shares Group 1 Group 2	5.5584 2.4065	- 3.1519	5.5584 5.5584	5.5432 5.5432

Group 1: shares purchased prior to 1 April 2019 Group 2: shares purchased on or after 1 April 2019

Distribution payable 31 May 2020	Net revenue pence per share	Equalisation pence per share	Net distribution payable 31.5.20 pence per share	Net distribution paid 31.5.19 pence per share
Accumulation shares (No Trail)	8.8236		8.8236	0.0222
Group 1 Group 2	2.6189	6.2047	8.8236	9.9233 9.9233
Z Accumulation shares Group 1 Group 2	4.1190 1.8681	- 2.2509	4.1190 4.1190	4.6296 4.6296
Y Accumulation shares Group 1 Group 2	4.1329 2.1397	- 1.9932	4.1329 4.1329	4.6440 4.6440
Income shares (No Trail) Group 1 Group 2	4.6969 0.3487	- 4.3482	4.6969 4.6969	5.5190 5.5190
Z Income shares Group 1 Group 2	3.5777 1.8620	- 1.7157	3.5777 3.5777	4.2025 4.2025
Y Income shares Group 1 Group 2	3.5886 1.7827	- 1.8059	3.5886 3.5886	4.2141 4.2141

Group 1: shares purchased prior to 1 October 2019

Group 2: shares purchased on or after 1 October 2019

Equalisation applies only to shares purchased during the distribution period (Group 2). It is the average amount of revenue included in the purchase price of all Group 2 shares and is refunded to holders of these shares as a return of capital. Being capital it is not liable to income tax. Instead, it must be deducted from the cost of shares for capital gains purposes.

Investment report for the year

The Investment Objective and Policy of the Invesco UK Strategic Income Fund (UK)

The Fund aims to produce an above average income and capital growth over the long term (5 years plus). The Fund invests at least 80% of its assets in shares or other equity related securities of companies incorporated, domiciled or carrying out the main part of their economic activity in the UK. In pursuing the Fund's investment objective, the fund manager may consider it appropriate to also invest in other transferable securities (including private and unlisted equities and non UK companies), money market instruments, collective investment schemes (including funds managed by the Invesco group), deposits and cash. The Fund may use derivatives for efficient portfolio management purposes only, to reduce risk, reduce costs and/or generate additional capital or income.

On the 7 August 2019 there was an update to the Prospectus for the various ICVC funds in light of the FCA's Asset Management Market Study. As part of this update, various changes were implemented regarding the Fund's investment objectives, investment policies, investment strategies and benchmark disclosures, all for clarification purposes only. There has been no changes to the way the Funds are managed as a result of these changes. The updated prospectus is available at www.invesco.co.uk. The investment objectives and policies currently shown within these financial statements are those that were in place as at 31 March 2020.

Performance ¹		'	'	Perc	entage growth
to 31 March 2020	Since 30.9.19 %	Since 31.3.19 %	Since 31.3.17 %	Since 31.3.15 %	Since 31.3.10 %
Invesco UK Strategic Income Fund (UK)					
(Z Accumulation shares) ²	-29.48	-31.06	-37.36	-32.08	36.86
IA UK All Companies Sector NR ³	-22.98	-19.15	-14.56	-1.57	56.15
Fund Ranking	218/239	226/237	221/227	209/214	137/172

Standardised rolling 12 month performance				Percer	ntage growth
	31.3.15	31.3.16	31.3.17	31.3.18	31.3.19
	31.3.16	31.3.17	31.3.18	31.3.19	31.3.20
	%	%	%	%	%
Invesco UK Strategic Income Fund (UK)					
(Z Accumulation shares) ²	1.3	7.0	-4.1	-5.2	-31.1
IA UK All Companies Sector NR ³	-2.5	18.1	2.7	2.9	-19.2

This standardised past performance information is updated on a quarterly basis. Should you require up to date past performance information, this is available on our website www.invesco.co.uk or by contacting us.

Fund and sector average performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. This may differ from the performance figure shown on page 58 for Z Accumulation shares as the figure above is based on the quoted 12pm price and the figure shown on page 58 is based on the close of business bid price.

The value of investments and any income from them will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.

Past performance is not a guide to future returns. Current tax levels and reliefs may change. Depending on individual circumstances, this may affect investment returns.

- Performance based on the Published Net Asset Value.
- Effective 18 April 2016, the primary share class changed from Income share (No Trail) class to Z Accumulation share class. Performance figures are based on the Z Accumulation share class. As this was launched on 12 November 2012, for the periods prior to this launch date, performance figures are based on the Income share (No Trail) class, without any adjustment for fees.
- This is a Comparator Benchmark. Given its geographic focus the Fund's performance can be compared against the Benchmark. However, the Fund is actively managed and is not constrained by any benchmark.

Investment report for the year

Strategy, review and outlook

The Fund fell in value during the year to the end of March 2020, under-performing the IA UK All Companies Sector NR.

Fund and sector average performance data source: Lipper, in Sterling, with income reinvested and net of the ongoing charge and portfolio transaction costs. Performance figures are based on the Z Accumulation share class.

Past performance is not a guide to future returns.

It has been a volatile 12 months for the UK equity market, dominated by concerns affecting the outlook for global economic growth. US-China trade relations, Brexit, and domestic politics were huge uncertainties in 2019, but 2020 so far has delivered the market shock that no one could have foreseen. The UK equity market fell in the first quarter of 2020 posting its biggest quarterly drop for more than three decades as the global economic costs of the Covid-19 pandemic continued to mount. Extreme levels of volatility were witnessed on an intraday basis, with swings in prices significantly large enough to impact 12-month returns.

Prior to the pandemic, employment growth in the UK looked set to remain firm, real wages were set to increase further, growth in government spending had picked up and investment spending was likely to strengthen. On this basis, overall rates of economic growth were expected to accelerate throughout the year. As the scale of the pandemic unfolded, however, governments around the world launched unprecedented stimulus measures in March, while central banks cut interest rates to support economic activity in the coming months. The strength and depth of the measures announced by the Chancellor and the Bank of England should provide material support to employment income and bank lending to the real economy.

Looking at the four main themes within the Fund: UK Domestic Value, International Growth Opportunities, Tobacco and Non-Correlated Financials, it follows that a number of companies within the UK Domestic Value theme performed positively over the 12 months. Tesco, Derwent London, Breedon and CLS all delivered positive returns, benefiting from the Conservative Party's emphatic election victory in December 2019 and greater clarity around Brexit. However, stocks within the theme which are more heavily exposed to sterling weakness, or those which have suffered from the impact of the virus, have tended to underperform (Capita, Victoria, Royal Bank of Scotland, Whitbread).

Some of the better performing stocks also included those within the International Growth Opportunities and Tobacco themes. Tobacco and Oil stocks, for example, tend to be more exposed to international earnings, which means that they are relative beneficiaries of \$US strength (British American Tobacco, Royal Dutch Shell). The International Growth Opportunities theme also includes HomeServe, a company engaged in providing home emergency, repair and heating installation services, and select health care stocks such as Novo Nordisk and Novartis, which have performed well. Health care is one of only two sectors to have delivered positive returns at the broad market level over the 12-month period. The absence of AstraZeneca and GlaxoSmithKline, however, impacted performance relative to the benchmark. Elsewhere, easyJet and

International Consolidated Airlines (IAG) also saw significant share price falls. The spread of Covid-19 and the measures to contain it have had a significant impact on the share price of the tourism and leisure industry (which includes air travel).

Meanwhile, the Non-Correlated Financials theme has exhibited a particularly wide range of outcomes. The investment platform AJ Bell, a longstanding investment for the Fund, saw strong share price growth, and online trading platform Plus500 performed well due to increased trading on CFDs (contract for difference) by people isolating at home. On the flipside, non-prime lenders such as Provident Financial tended to be weaker.

The Fund's positioning has evolved incrementally over the past year to best reflect the opportunities that the fund manager has seen in the market. It is frustrating that the performance of the Fund has lagged the wider stock market, however the fund manager remains confident in the composition of the fund and believes that it is crucial, in such times of extreme volatility and somewhat irrational market pricing, that the Fund remains rooted in the fundamental investment process.

The Fund continues to seek to invest in companies that have the potential to achieve both capital growth and sustainable growth in income over time. In investing across the market-cap spectrum, the risk profile of the fund is diversified, whilst also benefitting from diverse sources of income. The fund manager continues to seek the best opportunities to create a diversified, sustainable flow of dividend income that can grow over time.

Mark Barnett, Fund Manager

Where Mark Barnett has expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.

Effective 15 May 2020 Mark Barnett left Invesco, James Goldstone and Ciaran Mallon were appointed as Fund Managers.

The Fund's ten largest investments are	%
British American Tobacco	6.89
PureTech Health	5.92
BP	5.67
Oxford Genetics	4.45
Tesco	3.69
Randall & Quilter Investment	3.11
Derwent London	3.01
Legal & General	2.88
Next	2.51
HawkEye 360	2.50

Investment report for the year

Comparative tables	-	-	
Year ended Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share	•		
Opening net asset value per share	174.33	185.27	194.13
Return before operating charges* Operating charges	(46.82)	(7.83)	(5.55) (3.31)
	(2.83)	(3.11)	
Return after operating charges Distributions	(49.65) (7.06)	(6.21)	(8.86) (5.77)
Retained distributions on	(7.00)	(0.21)	(5.11)
accumulation shares	7.06	6.21	5.77
Closing net asset value per share	124.68	174.33	185.27
*After direct transaction costs of	(0.13)	(0.11)	(0.27)
Performance			
Return after charges	(28.48%)	(5.90%)	(4.56%)
Other information			
Closing net asset value (£'000)	8,789	20,182	36,767
Closing number of shares Operating charges	7,049,101 1.67%	11,577,212 1.67%	19,845,613 1.67%
Direct transaction costs	0.08%	0.06%	0.14%
Performance fee	-	-	-
Prices			
Highest share price	181.23	199.48	205.36
Lowest share price	109.97	165.72	184.06
Year ended Accumulation shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	704.27	744.71	776.46
Return before operating charges*	(189.97)	(31.65)	(22.44)
Operating charges	(8.03)	(8.79)	(9.31)
Return after operating charges Distributions	(198.00) (28.62)	(40.44) (25.05)	(31.75) (23.16)
Retained distributions on	(20.02)	(23.03)	(23.10)
accumulation shares	28.62	25.05	23.16
Closing net asset value per share	506.27	704.27	744.71
*After direct transaction costs of	(0.54)	(0.43)	(1.10)
Performance			
Return after charges	(28.11%)	(5.43%)	(4.09%)
Other information	1 100	4 5 40	0.407
Closing net asset value (£'000)	1,408	1,542	2,687
Closing number of shares Operating charges	278,165 1.17%	218,896 1.17%	360,870 1.17%
Direct transaction costs	0.08%	0.06%	0.14%
Performance fee	-	-	-
Prices	72425	000 44	022.00
Highest share price Lowest share price	734.35 446.44	802.41 668.64	822.09 739.78
Lowest share price	440.44	000.04	139.10

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued			
Year ended Z Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share		•	
Opening net asset value per share	315.76	333.06	346.40
Return before operating charges* Operating charges	(85.38) (2.83)	(14.21) (3.09)	(10.07) (3.27)
Return after operating charges	(88.21)	(17.30)	(13.34)
Distributions	(12.85)	(11.23)	(10.34)
Retained distributions on	(12.00)	(11.20)	(10.0 1)
accumulation shares	12.85	11.23	10.34
Closing net asset value per share	227.55	315.76	333.06
*After direct transaction costs of	(0.24)	(0.19)	(0.49)
Performance			
Return after charges	(27.94%)	(5.19%)	(3.85%)
Other information	21 000	40.166	01 550
Closing net asset value (£'000) Closing number of shares	21,980 9,659,591	49,166 15,570,475	81,552 24,485,836
Operating charges	0.92%	0.92%	0.92%
Direct transaction costs	0.08%	0.06%	0.14%
Performance fee	-	-	-
Prices			
Highest share price	329.87	358.99	366.92 330.83
Lowest share price	200.65	299.59	330.63
Year ended Y Accumulation shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	221.67	233.70	242.93
Return before operating charges* Operating charges	(59.96)	(9.98)	(7.06)
Return after operating charges	(1.88)	(2.05)	(2.17)
Distributions	(9.02)	(7.88)	(7.25)
Retained distributions on	(3.02)	(1.00)	(1.23)
accumulation shares	9.02	7.88	7.25
Closing net asset value per share	159.83	221.67	233.70
*After direct transaction costs of	(0.17)	(0.13)	(0.34)
Performance	(27.000()	/F 4 F0/\	(2.000()
Return after charges	(27.90%)	(5.15%)	(3.80%)
Other information Closing net asset value (£'000)	40,672	94,892	149,744
Closing number of shares	25,447,621	42,807,537	64,076,084
Operating charges	0.87%	0.87%	0.87%
Direct transaction costs	0.08%	0.06%	0.14%
Performance fee	_	-	-
Prices	221.66	251.04	257.25
Highest share price Lowest share price	231.66 140.93	251.94 210.30	257.35 232.13
Lowest share price	170.73	210.50	232.13

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued		-	
Year ended Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	114.90	126.29	136.38
Return before operating charges*	(30.11)	(5.09)	(3.76)
Operating charges	(1.84)	(2.10)	(2.31)
Return after operating charges Distributions	(31.95) (4.61)	(7.19) (4.20)	(6.07) (4.02)
Retained distributions on	(4.01)	(4.20)	(4.02)
accumulation shares	-	-	_
Closing net asset value per share	78.34	114.90	126.29
*After direct transaction costs of	(0.09)	(0.07)	(0.19)
Performance			
Return after charges	(27.81%)	(5.69%)	(4.45%)
Other information			
Closing net asset value (£'000)	6,745	17,969	39,017
Closing number of shares	8,610,403	15,639,211	30,894,482
Operating charges	1.67%	1.67%	1.67%
Direct transaction costs Performance fee	0.08%	0.06%	0.14%
Prices			
Highest share price	119.45	135.98	144.27
Lowest share price	70.67	110.93	127.20
Year ended Income shares (No Trail)	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	464.24	507.70	545.52
Return before operating charges*	(122.21)	(20.57)	(15.17)
Operating charges	(5.23)	(5.94)	(6.49)
Return after operating charges	(127.44)	(26.51)	(21.66)
Distributions	(18.67)	(16.95)	(16.16)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	318.13	464.24	507.70
*After direct transaction costs of	(0.35)	(0.29)	(0.76)
Performance			
Return after charges	(27.45%)	(5.22%)	(3.97%)
Other information			
Closing net asset value (£'000)	12,811	22,354	30,313
Closing number of shares	4,026,974	4,815,261	5,970,512
Operating charges	1.17%	1.17%	1.17%
Direct transaction costs Performance fee	0.08%	0.06%	0.14%
Prices			
Highest share price	482.83	547.06	577.61
Lowest share price	286.94	447.61	511.32

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Investment report for the year

Comparative tables continued		1	
Year ended Z Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	255.10	278.29	298.27
Return before operating charges*	(67.31)	(11.32)	(8.35)
Operating charges	(2.26)	(2.56)	(2.79)
Return after operating charges	(69.57)	(13.88)	(11.14)
Distributions	(10.28)	(9.31)	(8.84)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	175.25	255.10	278.29
*After direct transaction costs of	(0.19)	(0.16)	(0.42)
Performance			
Return after charges	(27.27%)	(4.99%)	(3.73%)
Other information			
Closing net asset value (£'000)	7,399	27,526	50,429
Closing number of shares	4,221,943	10,790,290	18,121,354
Operating charges	0.92%	0.92%	0.92%
Direct transaction costs	0.08%	0.06%	0.14%
Performance fee	_	-	-
Prices			
Highest share price	265.37	299.97	315.95
Lowest share price	158.05	245.80	280.25
Year ended Y Income shares	31.3.20 (pence per share)	31.3.19 (pence per share)	31.3.18 (pence per share)
Change in net assets per share			
Opening net asset value per share	185.38	202.14	216.54
Return before operating charges*	(48.94)	(8.24)	(6.06)
Operating charges	(1.55)	(1.76)	(1.92)
Return after operating charges	(50.49)	(10.00)	(7.98)
Distributions	(7.47)	(6.76)	(6.42)
Retained distributions on accumulation shares	_	_	_
Closing net asset value per share	127.42	185.38	202.14
*After direct transaction costs of	(0.14)	(0.11)	(0.30)
Performance			
Return after charges	(27.24%)	(4.95%)	(3.69%)
Other information			
Closing net asset value (£'000)	6,794	20,866	41,193
Closing number of shares	5,331,674	11,255,668	20,378,598
Operating charges	0.87%	0.87%	0.87%
Direct transaction costs Performance fee	0.08%	0.06%	0.14%
Prices			
Highest share price	192.86	217.92	229.40
Lowest share price	114.92	178.61	203.56

Direct transaction costs comprise commission and taxes, principally applicable to equity investment purchases and sales. Shareholders should note that additionally there are other transaction costs such as dealing spread and underlying costs with regard to Collective Investment Scheme holdings which will also have reduced the Fund and share class returns before operating charges.

Invesco UK Strategic Income Fund (UK) Investment report for the year

Denmark 2.31% (31.3.19 - Nil) Financials 2.31% (31.3.19 - Nil) Now Nordisk 'B 50,936 2,463 2.31	Portfolio Statement (Unaudited) as at 31 March 2020	Holding or nominal value of	Market value	Percentage of total net assets
Financials 2.31% (31.3.19 - Nii)	Investment Denmark 2 2104 (21 2 10 - Nii)	positions	£'000	%
Novo Nordisk 'B' 50,936 2,463 2,31 France 1.88% (31.3.19 - Nii) Oil & Gas 1.68% (31.3.19 - Nii) Total 64,366 2,008 1.88 Guernsey Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - Nii) Health Care 1.67% (31.3.19 - Nii) Novartis 26,727 1,779 1.67 United Kingdom 85,73% (31.3.19 - 7.37%) Oli & Gas 8.05% (31.3.19 - 3.52%) BP 1,759,749 6,044 5.67 Royal Dutch Shell 'A' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.44 Royal Dutch Shell 'B' (UK Regd.) 48,121 1.969 1.85 Consumer Goods 10,39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.99 Consumer Services 9.53% (31.3.19 - 3.47%) Oxford Genetics 'C-2" 10,200 4,118 0.89 Consumer Services 9.53% (31.3.19 - 9.18%) easy, Jet 1,204 0.39,33 3.69 Royal Dutch Shell 'A' (UK Regd.) 39,115 1.185 1.111 Telecommunications 1.64% (31.3.19 - 3.01%) Br 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax Andro Genetics 'C-2" 1.51 1.626 1.73 Royal Dutch Shell 'A' (UK Regd.) 46,177 1.80 1.74 Royal Dutch Shell 'A' (UK Regd.) 46,177 1.80 1.74 Royal Dutch Shell 'A' (UK Regd.) 46,177 1.80 1.74 Royal Dutch Shell 'A' (UK Regd.) 46,177 1.80 1.74 Royal Dutch Shell 'A' (UK Regd.) 46,177 1.80 1.74 Roya	· · · · · · · · · · · · · · · · · · ·			
Total 1,88	· · · · · · · · · · · · · · · · · · ·	50,936	2,463	2.31
Total 64,366 2,008 1.88	· · · · · · · · · · · · · · · · · · ·			·····
Suernsey Nil (31.3.19 - 0.00%) Financials Nil (31.3.19 - 13.82%) Financials Nil (31.3.19 - 11.36%) Financials Nil (31.3.19 - 3.47%) Financials Nil (31.3.19 - 3.40%) Financials Nil (31.3.19 - 3.40%) Financials Nil (31.3.19 - 3.40%) Fin	· · · · · · · · · · · · · · · · · · ·	64.366	2.008	1.88
Straid Nil (31.3.19 - 0.00%) Straid Nil (31.3.19 - 0.06%) Health Care Nil (31.3.19 - 0.00%) Switzerland 1.67% (31.3.19 - Nil) Health Care 1.67% (31.3.19 - Nil) Novartis Z6,727 1,779 1.67 Nil (31.3.19 - Nil) Novartis Z6,727 1,779 1.67 Nil (36.88.05% (31.3.19 - 8.52%) Straid Nil (31.3.19 - 3.82%) Straid Nil (31.3.19 - 3.47%) Straid Nil			_,000	
Financials Nii (31.3.19 - 0.00%) Financials Nii (31.3.19 - 0.16%) Switzerland 1.67% (31.3.19 - Nii) Health Care 1.67% (31.3.19 - Nii) Novartis 26,727 1,779 1.67 United Kingdom 85.73% (31.3.19 - 97.37%) 018	•			
Switzerland 1.67% (31.3.19 - Nii) Health Care 1.67% (31.3.19 - Nii) Novartis 26,727 1,779 1.67 United Kingdom 85.73% (31.3.19 - 97.37%) Oil & Gas 8.05% (31.3.19 - 8.52%) BP 1,759,749 6,044 5.67 Royal Dutch Shell 'A' (UK Regd.) 48,421 687 0.64 Royal Dutch Shell 'B' (UK Regd.) 48,421 687 0.64 Royal Dutch Shell 'B' (UK Regd.) 443,022 1.695 1.74 Industrials 7.98% (31.3.19 - 13.82%) Babcock International 443,022 1.695 1.74 Industrials 6.50 1.74 Industrials 7.98% (31.3.19 - 11.82%) Babcock International 443,022 1.695 1.74 Industrials 7.98% (31.3.19 - 11.82%) Babcock International 3,470,782 2,318 2.18 Capita 3,010,745 985 0.92 Eddie Stobart Logistics 3,654,583 406 0.32 Eddie Stobart Logistics 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Robride 2,090,807 1,152 1.08 Rexeon 19,636 83 0.08 Rexeon 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C-2' 1 10,200 4,118 3.86 Consumer Services 9.53% (31.3.19 - 9.18%) easyJet 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easyJet 391,298 842 0.79 Next 65,754 2,677 2.51 Fesco 1,720,440 3,933 3.69 Whitbread 391,298 842 0.79 Next 65,754 2,677 2.51 Fesco 1,720,440 3,933 3.69 Whitbread 391,15 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT Utilities 3.33% (31.3.19 - 1.72%) Drax 76,016 1,193 1.12 National Grid 45,573 431 0.40 SEE 1,720,440 1,935 1.12 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 43,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Loes and 1.525 1.25 Loes and 1.525 1.525 Loes and 1.525 1.525 Loes and 1.525 1.525 Loes and 1.525 1.525 Loes and 1.526 1.43 Burford Capital 319,528 1.337 1.25 Loes and 1.526 1.43 Burford Capital 319,528 1.337 2.25				
Health Care 1.67% (31.3.19 - Nil) Novartis 26,727 1,779 1.67 United Kingdom 85.73% (31.3.19 - 97.37%) Dil & Cas 8.05% (31.3.19 - 8.52%) BP	Financials Nil (31.3.19 - 0.46%)			
Novartis 26,727 1,779 1.67				
Oil & Gas 8.05% (31.3.19 - 8.52%) BP 1,759,749 6,044 5.67 Royal Dutch Shell 'A' (UK Regd.) 48,421 687 0.64 Royal Dutch Shell 'B' (UK Regd.) 136,425 1,855 1.74 Industrials 7.98% (31.3.19 - 13.82%) Babcock International 443,022 2,695 1.59 Breedon 3,470,782 2,318 2.18 Capita 3,010,745 985 0.92 Eddle Stobart Logistics 3,654,583 406 0.38 G4S 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Consumer Goods 10.39% (31.3.19 - 3.47%) Oxford Genetics 'C1 10,200 4,118 3.86 Oxford Genetics 'C21 1,526 8 0.59 Consumer Services 9.53%	· · · · · · · · · · · · · · · · · · ·	26,727	1,779	1.67
BP 1,759,749 6,044 5,67 Royal Dutch Shell 'A' (UK Regd.) 48,421 687 0.64 Royal Dutch Shell 'B' (UK Regd.) 136,425 1,855 1,74 Industrials 7.98% (31.3.19 - 13.82%) 3,470,782 2,318 2,18 Breedon 3,470,782 2,318 2,18 Capita 3,010,745 985 0,92 Eddie Stobart Logistics 3,654,583 406 0.38 G4S 1,219,587 1,25 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) 365,502 1,042 0,98 McBride 2,090,807 1,152 1.08 McBride 2,090,807 1,152 1.08 McBride 2,090,807 1,152 1.08 McBride 2,090,807 1,152 1.08 McBride 2,090,807 1,453 1.38 Oxford Genetics 'C' 1 1,020 4,118 3.86 Oxford Genetics 'C' <td< td=""><td></td><td></td><td></td><td></td></td<>				
Royal Dutch Shell 'B' (UK Regd.) 136,425 1,855 1.74 Industrials 7.98% (31.3.19 - 13.82%) Sabcock International 443,022 1,695 1.59 Babcock International 3,470,782 2,318 2.18 Capita 3,010,745 985 0.92 Eddie Stobart Logistics 3,654,583 406 0.38 G4S 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) Sritish American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0.98 McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 10,200 4,118 3.86 Oxford Genetics 'C¹ 10,200 4,118 3.86 Oxford Genetics 'C²¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) Easy, Jet 267,310 1,526 1,43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,93 3,69 Whitbread 39,115 1,185 1,11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Spitish Land 645,699 2,171 2.04 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1,25 Chesnara 823,669 2,397 2.25	· · · · · · · · · · · · · · · · · · ·	1,759,749	6,044	5.67
Industrials 7.98% (31.3.19 - 13.82%) Babcock International 443,022 1,695 1.59 Breedon 3,470,782 2,318 2,18 2,18 3,010,745 985 0,92 2,2018 3,010,745 985 0,92 2,2018 3,010,745 985 0,92 2,2018 3,010,745 985 0,92 2,2018 3,010,745 985 0,92 2,2018 3,010,745 985 0,92 3,010,745 985 0,92 3,010,745 985 0,92 3,010,745 985 0,92 3,010,745 3,010,745 3,010,745 3,010,745 3,010,745 3,010,745 3,010,745 3,025 3,045		•		0.64
Babcock International 443,022 1,695 1.59 Breedon 3,470,782 2,318 2.18 Capita 3,010,745 985 0.92 Eddie Stobart Logistics 3,654,583 406 0.38 G4S 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0.98 McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4,45% (31.3.19 - 3.47%) Oxford Genetics 'C¹-2' 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy.Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Financials 40.3	Royal Dutch Shell 'B' (UK Regd.)	136,425	1,855	1.74
Breedon 3,470,782 2,318 2.18 Capita 3,010,745 985 0,92 Eddie Stobart Logistics 3,654,583 406 0,38 G4S 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0,98 McBride 2,990,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C¹² 10,200 4,118 3.86 Oxford Genetics 'C²²¹ 10,200 4,118 3.86 Oxford Genetics 'C²²¹ 10,200 4,118 3.86 Oxford Genetics 'C²²¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy,Jet 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy,Jet 1,726 1,526 1.43 Interpolational	· · · · · · · · · · · · · · · · · · ·			
Capita 3,010,745 985 0,92 Eddie Stobart Logistics 3,654,583 406 0,38 G4S 1,219,587 1,125 1,06 HomeServe 186,134 1,969 1,85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0,98 McBridge Properties 365,502 1,453 1,36 McBridge Properties 365,502 1,415 3.86 Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">C				
Eddie Stobart Logistics 3,654,583 406 0.38 G4S 1,219,587 1,125 1.06 HomeServe 186,134 1,969 1.85 Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0.98 McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C¹ 10,200 4,118 3.86 Oxford Genetics 'C-2¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.				
HomeServe 186,134 1,969 1.85		3,654,583	406	
Consumer Goods 10.39% (31.3.19 - 11.36%) British American Tobacco Countryside Properties 365,502 1,042 0,98 McBride 2,090,807 1,152 1,08 Nexeon¹ 19,636 83 0,08 Victoria 695,208 1,453 1,36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C'¹ 10,200 0xford Genetics 'C-2'¹ 10,200 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy,Jet International Consolidated Airlines (UK Regd.) Next 65,754 2,677 2,51 Tesco 1,720,440 3,933 3,69 Whitbread 1,481,054 1,746 1,481 0,40 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1,12 National Grid SSE 147,619 1,925 1,81 Financials 40.36% (31.3.19 - 46.29%) Aviva Beazley 463,177 1,806 1,69 British Land 645,699 2,171 2,04 Burford Capital 1,495 1,526 1,43 1,495 1,495 1,496 1,496 1,496 1,497 1,49				1.06
British American Tobacco 266,282 7,341 6.89 Countryside Properties 365,502 1,042 0.98 McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C¹¹ 10,200 4,118 3.86 Oxford Genetics 'C-2¹¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy.Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 <td< td=""><td>nomeserve</td><td>100,134</td><td>1,909</td><td>1.05</td></td<>	nomeserve	100,134	1,909	1.05
Countryside Properties 365,502 1,042 0,98 McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C¹ 10,200 4,118 3.86 Oxford Genetics 'C²¹ 10,200 4,118 3.86 Oxford Genetics 'C²²¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy.Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 Nati	· · · · · · · · · · · · · · · · · · ·	244 222	7.044	
McBride 2,090,807 1,152 1.08 Nexeon¹ 19,636 83 0.08 Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C¹¹ 10,200 4,118 3.86 Oxford Genetics 'C-2¹¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easy_Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692				
Victoria 695,208 1,453 1.36 Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C'¹ 10,200 4,118 3.86 Oxford Genetics 'C-2'¹ 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easyJet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 776,016 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25		2,090,807		1.08
Health Care 4.45% (31.3.19 - 3.47%) Oxford Genetics 'C'1				0.08
Oxford Genetics 'C'1 10,200 4,118 3.86 Oxford Genetics 'C-2'1 1,531 628 0.59 Consumer Services 9.53% (31.3.19 - 9.18%) easyJet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara	Victoria	695,208	1,453	1.36
Consumer Services 9.53% (31.3.19 - 9.18%) easy Jet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				
Consumer Services 9.53% (31.3.19 - 9.18%) easyJet 267,310 1,526 1.43 International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				
easy Jet	Oxidia defletics C 2	1,551	020	0.59
International Consolidated Airlines (UK Regd.) 391,298 842 0.79 Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25		267.210	1 526	1 42
Next 65,754 2,677 2.51 Tesco 1,720,440 3,933 3.69 Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				
Whitbread 39,115 1,185 1.11 Telecommunications 1.64% (31.3.19 - 3.01%) BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25			2,677	2.51
Telecommunications 1.64% (31.3.19 - 3.01%) BT				3.69
BT 1,481,054 1,746 1.64 Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	whitbread	39,115	1,185	1.11
Utilities 3.33% (31.3.19 - 1.72%) Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	· · · · · · · · · · · · · · · · · · ·			
Drax 776,016 1,193 1.12 National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	ВТ	1,481,054	1,746	1.64
National Grid 45,573 431 0.40 SSE 147,619 1,925 1.81 Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	Utilities 3.33% (31.3.19 - 1.72%)			
Financials 40.36% (31.3.19 - 46.29%) Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				1.12
Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				1.81
Aviva 592,692 1,591 1.49 Beazley 463,177 1,806 1.69 British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	Financials 40.36% (31.3.19 - 46.29%)			
British Land 645,699 2,171 2.04 Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25	Aviva			1.49
Burford Capital 319,528 1,337 1.25 Chesnara 823,669 2,397 2.25				
Chesnara 823,669 2,397 2.25				
				2.25
	CLS			1.90

Investment report for the year

Portfolio Statement (Unaudited) continued as at 31 March 2020	Holding or nominal value of	Market value	Percentage of total net assets
Investment	positions	£'000	%
Financials continued	00.005	2 242	2.04
Derwent London	98,305	3,213	3.01
Eurovestech ¹	550,537	20	0.02
Hadrians Wall Secured Investments Fund	2,653,577	1,194	1.12
Hiscox	141,160	1,306	1.23
IP	3,324,757	1,662	1.56
Land Securities	116,263	647	0.61
Legal & General	1,583,412	3,069	2.88
Marwyn Value Investors	3,647,503	2,663	2.50
NewRiver REIT	1,416,899	846	0.79
Oakley Capital Investments	582,322	1,112	1.04
Phoenix Spree Deutschland	869,293	2,334	2.19
Pollen Street Secured Lending	322,430	2,251	2.11
Provident Financial	676,470	1,467	1.38
Randall & Quilter Investment	2,207,227	3,311	3.11
Real Estate Investors	6,926,290	2,493	2.34
Royal Bank of Scotland	1,151,427	1,300	1.22
Urban Exposure	2,925,211	995	0.93
Zegona Communications	2,268,945	1,815	1.70
United States 8.43% (31.3.19 - 2.40%) Basic Materials Nil (31.3.19 - 0.00%)			
Industrials 2.50% (31.3.19 - 0.45%)			
HawkEye 360 ¹	558,838	2,664	2.50
Health Care 5.93% (31.3.19 - 1.95%)			
Ecoeos ¹	1,190,476	-	0.00
Ecoeos warrants 16/5/2023 ¹	593,928		0.00
Jaguar Health	25,604	10	0.01
Jaguar Health – Tranche A Convertible Contingent rights ¹	740,281	-	0.00
Jaguar Health – Tranche B Convertible Contingent rights ¹	1,578,372	-	0.00
Jaguar Health indemnity shares ¹	305,182	-	0.00
Lombard Medical ¹	1,371,382	2	0.00
PureTech Health	2,627,164	6,305	5.92
Portfolio of investments (31.3.19 - 100.23%)		106,615	100.02
Net other liabilities (31.3.19 - (0.23%))		(17)	(0.02)
Net assets		106,598	100.00

Unless otherwise stated, all holdings are on an official stock exchange listing or are permitted collective investment schemes.

Unquoted securities - for the year ended 31 March 2020 these amount to 7.05%
 (31 March 2019 - 2.01%) of the Net Asset Value of the Fund.

Portfolio Statement Breakdown as at 31 March 2020	Market value 31.3.20 £'000	Percentage of total net assets 31.3.20 %	Market value 31.3.19 £'000	Percentage of total net assets 31.3.19 %
Quoted securities	99,100	92.97	249,958	98.22
Unquoted securities	7,515	7.05	5,124	2.01
Portfolio of investments	106,615	100.02	255,082	100.23
Net other liabilities	(17)	(0.02)	(585)	(0.23)
Net assets	106,598	100.00	254,497	100.00

Invesco UK Strategic Income Fund (UK) Investment report for the year

Summary of Material Portfolio Changes	
for the year 1 April 2019 to 31 March 2020	Cost £'000
Total purchases	21,408
Purchases:	
Denmark Novo Nordisk 'B'	2,421
France Total	3,162
Israel Plus500	251
Switzerland	
Novartis	1,938
United Kingdom SSE International Consolidated Airlines (UK Regd.) Royal Dutch Shell 'B' (UK Regd.) Whitbread Countryside Properties Royal Bank of Scotland Land Securities Tesco National Grid Aviva British American Tobacco easyJet BP Drax Amigo	2,273 2,153 1,757 1,594 1,508 1,061 1,052 613 418 354 229 207 172 170 75
	Proceeds £'000
Total sales	120,535
Largest sales:	
United Kingdom	
BCA Marketplace	7,017
Next	5,670
Imperial Brands British American Tobacco	5,456 4,752
BP	4,661
Royal Dutch Shell 'A' (UK Regd.)	4,095
Real Estate Investors	4,055
NewRiver REIT Equiniti	3,904 3,736
Legal & General	3,469
Derwent London	3,158
HomeServe	3,140
TalkTalk Telecom Tesco	3,122 2,842
Zegona Communications	2,700
Aviva	2,646
Whitbread	2,629
Phoenix Spree Deutschland	2,592
Allergy Therapeutics Randall & Quilter Investment	2,579 2,543
Nandan a gunter investment	2,545

Invesco UK Strategic Income Fund (UK) Financial statements

Retained distribution on accumulation shares

Closing net assets attributable to Shareholders

Unclaimed distribution monies

Statement of Total Return for the year 1 April 2019 to 31 March 2020	Notes	£'000	01.4.19 to 31.3.20 £'000	£′000	01.4.18 to 31.3.19 £'000
Income					
Net capital losses	2		(49,511)		(22, 123)
Revenue	3	8,238		12,156	
Expenses	4	(1,960)		(3,756)	
Interest payable and similar charges	5	(5)		(9)	
Net revenue before taxation		6,273		8,391	
Taxation	6	(95)		(57)	
Net revenue after taxation			6,178		8,334
Total return before distributions			(43,333)		(13,789)
Distributions	7		(7,935)		(11,802)
Chatanana da Chamania Nada Anada Add					
Statement of Change in Net Assets Atta to Shareholders for the year 1 April 2019 to 31 March 2020	ributable	£'000	01.4.19 to 31.3.20 £'000	£'000	01.4.18 to 31.3.19 £'000
Opening net assets attributable to Sha	reholders		254,497		431,702
Amounts received on issue of shares		3,136		10,839	
Amounts paid on redemption of shares		(105,060)		(170,253)	
			(101,924)		(159,414)
Dilution adjustment Change in net assets attributable to			511		946
Shareholders from investment activities					

4,780

106,598

254,497

Invesco UK Strategic Income Fund (UK) Financial statements

Balance Sheet as at 31 March 2020	Notes	£′000	31.3.20 £'000	٤′000	31.3.19 £'000
Assets					
Fixed assets Investments			106,615		255,082
Current assets		2.222			
Debtors	8	2,993		1,156	
Cash and bank balances	9	247		664	
Total other assets			3,240		1,820
Total assets			109,855		256,902
Liabilities					
Investment liabilities			-		-
Creditors					
Distribution payable		769		1,381	
Other creditors	10	2,488		1,024	
Total other liabilities			3,257		2,405
Total liabilities			3,257		2,405
Net assets attributable to Shareholders			106,598		254,497

Notes to the financial statements

Refer to pages 06 to 15 for notes applicable to the financial statements of all Funds.

1 Accounting Policies

The Fund's Accounting Policies, Distribution Policies and Generic Risk Factors are set out on pages 06 to 13.

2 Net capital losses	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Foreign currency gains/(losses)	33	(16)
Non-derivative securities	(49,544)	(22,107)
Net capital losses	(49,511)	(22,123)

3 Revenue	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Bank interest	-	5
Interest distributions from authorised Funds	175	358
Management fee rebates	129	155
Non-taxable overseas dividends	1,340	1,733
Stock dividends	111	-
Taxable overseas dividends	93	75
UK dividends	5,270	8,221
UK REIT dividends	1,120	1,609
	8,238	12,156

4 Expenses	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Payable to the Manager, associates of the Manager and agents of either of them: Fund Management Fee ¹	1.960	3,756
	1,960	3,756
Total expenses	1,960	3,756

Total audit fees of £12,500 (2019 - £10,676) exclusive of VAT payable to the auditors for the year ended 31 March 2020 are borne out of the Fund Management Fee.

Notes to the financial statements

5	Interest payable and similar charges	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Inte	erest	5	9

6 Taxation	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
a) Analysis of charge for the year		
Overseas tax	95	57
Total tax charge	95	57

There is no corporation tax charge for the year (2019 - Nil).

b) Factors affecting the tax charge for the year

The tax assessed for the year is lower (2019 - lower) than the standard rate of corporation tax in the UK for an authorised investment company with variable capital. The differences are explained below:

	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Net revenue before taxation	6,273	8,391
Corporation tax at 20% (2019 -20%)	1,255	1,678
Effects of: Movement in excess expenses Overseas tax Prior year adjustment Relief on overseas tax expensed Revenue not subject to tax	97 95 (3) (5) (1,344)	313 57 - - (1,991)
Total tax charge	95	57

Authorised investment companies with variable capital are exempt from tax on capital gains. Therefore any capital return is not included in the above reconciliation.

c) Deferred tax

At the year end the Fund had surplus management expenses of £54,893,000 (2019 - £54,407,000). It is unlikely that the Fund will generate sufficient taxable profits in the future to utilise these expenses and therefore a deferred tax asset of £10,979,000 (2019 - £10,882,000) has not been recognised.

7 Distributions	01.4.19 to 31.3.20 £'000	01.4.18 to 31.3.19 £'000
Accumulations and distributions paid 30 November 2019 Accumulations and distributions payable 31 May 2020	4,710 2,392	6,798 3,924
Amounts deducted on redemption of shares Amounts received on issue of shares	7,102 1,081 (248)	10,722 1,452 (372)
	7,935	11,802
The distributable amount has been calculated as follows:		
Net revenue after taxation	6,178	8,334
Fund Management Fee taken to capital	1,960	3,756
Tax relief on expenses taken to capital	(203)	(288)
	7,935	11,802

Notes to the financial statements

8 Debtors	31.3.20 £'000	31.3.19 £′000
Accrued revenue	289	604
Amounts receivable for issue of shares	639	4
Foreign currency contracts awaiting settlement	106	-
Overseas tax recoverable	74	51
Sales awaiting settlements	1,885	497
	2,993	1,156

9	Cash and bank balances	31.3.20 £'000	31.3.19 £'000
Ca	sh and hank halances	247	664

10 Other creditors	31.3.20 £′000	31.3.19 £'000
Accrued expenses	103	233
Amounts payable for redemption of shares	538	791
Foreign currency contracts awaiting settlement	106	_
Purchases awaiting settlement	1,741	-
	2.488	1.024

11 Commitments, contingent liabilities and contingent assets

There were no commitments, contingent liabilities or contingent assets at the balance sheet date (2019 - Nil).

12 Related parties

Related party interests in the Fund are disclosed in note 10 of the notes applicable to the financial statements of all Funds on page 14. Amounts payable to Invesco Fund Managers Limited in respect of Fund Management Fees are disclosed in note 4. Amounts due at the end of the accounting year for Fund Management Fees of £103,000 (2019 - £233,000) are disclosed in note 10 within accrued expenses.

13 Generic Risk factors

As one of the key objectives of the Fund is to provide income, the Manager's ongoing charge is taken from capital rather than income. This can erode capital and reduce the potential for capital growth.

The Fund may invest in private and unlisted equities which may involve additional risks such as lack of liquidity, lack of pricing transparency, less readily available information on the company and concentrated ownership. These investments may result in greater fluctuations of the value of the Fund. The Manager, however, will ensure that any investments in private and unlisted equities do not materially alter the overall risk profile of the Fund.

The Fund may use derivatives (complex instruments) in an attempt to reduce the overall risk of their investments, reduce the costs of investing and/or generate additional capital or income, although this may not be achieved. The use of such complex instruments may result in greater fluctuations of the value of the Fund. The Manager, however, will ensure that the use of derivatives within the Fund does not materially alter the overall risk profile of the Fund.

The risk factors relating to the Fund are discussed more fully in note 5 of the notes applicable to the financial statements of all Funds on pages 10 to 13.

a) Counterparty risk

The Fund was not exposed to any counterparty risk as at the balance sheet date (2019 - Nil).

Notes to the financial statements

13 Generic Risk factors continued

b) Valuation of financial instruments

The categorisation of financial instruments in the tables below reflect the basis of valuation of instruments used to measure their fair value.

	Assets £'000	Liabilities £'000
31.3.20		
Level 1: Quoted prices	99,100	-
Level 2: Observable market data	· -	_
Level 3: Unobservable data	7,515	-
	106,615	-
31.3.19		
Level 1: Quoted prices	249,958	_
Level 2: Observable market data	_	_
Level 3: Unobservable data	5,124	-
	255,082	-

The majority of financial instruments are classified as level 1: Quoted prices. Instruments classified as level 3: Unobservable data mainly comprise non-market traded and unquoted securities.

Generally for the non-market traded and unquoted securities, where there is no price source from an active market for an investment, the Manager has applied judgement in determining the fair value. The Manager has used several valuation methodologies as prescribed in the International Private Equity and Venture Capital valuation guidelines to arrive at their best estimate of fair value. Valuation techniques used by the Manager are set out in Accounting Policies note 1 (i). The fair value is established by using measures of value such as:

- Price of recent transactions Management determine the fair value based on the price of recent transactions made by management or a third party.
- Milestone analysis Management assess the investment company's progress against milestones expected
 at the time of investment in order to determine whether an adjustment is required to the transaction price
 to determine fair value.
- Multiples Earnings or Revenue multiples are selected from comparable public companies based on geographic location, industry, size, risk profile, earnings growth prospects, target markets and other factors that management consider reasonable. A discount for lack of liquidity may then be applied to represent the adjustment to comparable company multiples to reflect the illiquidity of the portfolio companies relative to the comparable peer group. Management determines the discount for lack of liquidity based on its judgement, after considering market liquidity conditions and company specific factors such as the development stage of the portfolio company. One of the most common forms of multiples used for cash generating companies are EV/EBITDA multiples as EBITDA is generally seen to represent a good proxy for free cash flow. These are applied where appropriate based on the development of underlying portfolio companies but other multiples such as EV/Revenue may also be considered.
- Net assets Management determine the fair value based on the net asset value of the underlying portfolio company.

In applying the above valuation techniques in arriving at the fair value the Manager has assessed any further information available from internal and external sources to arrive at an estimated fair value, which includes but is not limited to the following:

- Reference to listed securities of the same company.
- Consideration of seniority of the securities held and terms of repayment upon realisation.
- Consideration of any trading restrictions on the investment company's shares that would limit Invesco's ability to realise its holding.
- Consideration of any outstanding payments to be made by Invesco.
- Industry statistics or events (such as mergers and acquisitions).

Invesco UK Strategic Income Fund (UK) Notes to the financial statements

14 Portfolio transaction costs for the year 1 April 2019 to 31 March 2020

Purchases (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments	21,331	11	0.05	66	0.31
Total purchases	21,331	11		66	
Total purchases including transaction costs	21,408				
Sales (excluding derivatives)	Transaction Value £'000	Commissions £'000	%	Taxes £'000	%
Equity instruments Collective investment schemes	113,206 7,401	66 5	0.06 0.07	1 -	0.00
Total sales	120,607	71		1	
Total sales net of transaction costs	120,535				
Derivative transaction costs		-		-	
Total transaction costs		82		67	
Total transaction costs as a % of average net assets		0.04%		0.04%	

Notes to the financial statements

14 Portfolio transaction costs continued

for the year 1 April 2018 to 31 March 2019

	Transaction				
	Value	Commissions		Taxes	
Purchases (excluding derivatives)	90013	000ع	%	£'000	%
Equity instruments	35,582	13	0.04	107	0.33
Collective investment schemes	153	-	-	-	-
Total purchases	35,735	13		107	
Total purchases including					
transaction costs	35,855				
	Transaction				
	Value	Commissions		Taxes	
Sales (excluding derivatives)	2'000	£'000	%	9000	%
Equity instruments	179,046	81	0.05	1	0.00
Collective investment schemes	8,316	2	0.03	0	0.00
Total sales	187,362	83		1	
Total sales net of					
transaction costs	187,278				
Derivative transaction costs		-		-	
Total transaction costs		96		108	
Total transaction costs					
as a % of average net assets		0.03%		0.03%	

The above analysis covers any direct transaction costs suffered by the Fund during the year. However it is important to understand the nature of other transaction costs associated with different investment asset classes and instruments types.

Separately identifiable direct transaction costs (commissions and taxes etc.) are attributable to the Fund's purchase and sale of equity shares. Additionally for equity shares, there is a dealing spread cost (the difference between the buying and selling prices) which will be suffered on purchase and sale transactions.

For the Fund's investment transactions in debt and money market instruments any applicable transaction charges form part of the dealing spread for these instruments. Transactions in money market instruments, cash and short-term collective investment schemes utilised as part of a daily sweep to manage the Fund's daily liquidity position are excluded from the analysis.

For the Fund's investment in collective investment scheme holdings there will potentially be dealing spread costs applicable to purchases and sales. However, additionally there are indirect transaction costs suffered in those underlying Funds, throughout the holding period for the instruments, which are not separately identifiable and do not form part of the analysis above.

Dealing spread costs suffered by the Fund vary considerably for the different asset/instrument types depending on a number of factors including transaction value and market sentiment.

At the balance sheet date the average portfolio dealing spread (difference between bid and offer prices of all investments expressed as a percentage of the offer price value) was 1.37% (2019 - 0.79%).

Invesco UK Strategic Income Fund (UK) Notes to the financial statements

15 Share movement for the year 1 April 2019 to 31 March 2020

	Accumulation shares	Accumulation shares (No Trail)	Z Accumulation shares	Y Accumulation shares
Opening shares	11,577,212	218,896	15,570,475	42,807,537
Shares issued Shares redeemed Shares converted	68,266 (3,898,626) (697,751)	1,548 (84,004) 141,725	331,671 (6,289,800) 47,245	373,421 (17,761,970) 28,633
Closing shares	7,049,101	278,165	9,659,591	25,447,621
	Income shares	Income shares (No Trail)	Z Income shares	Y Income shares
Opening shares	15,639,211	4,815,261	10,790,290	11,255,668
Shares issued Shares redeemed Shares converted	69,156 (6,372,765) (725,199)	122,527 (1,071,506) 160,692	259,321 (6,830,431) 2,763	157,861 (6,122,896) 41,041
Closing shares	8,610,403	4,026,974	4,221,943	5,331,674

16 Post balance sheet events

The Fund's post balance sheet events are set out on page 15.

Invesco UK Strategic Income Fund (UK) Distribution tables

Distribution tables for the year 1 April 2019 to 31 March 2020

Distribution paid 30 November 2019	Net revenue pence per share	Equalisation pence per share	Net distribution paid 30.11.19 pence per share	Net distribution paid 30.11.18 pence per share
Accumulation shares	4.0004		4 0004	0 = 0 0 0
Group 1 Group 2	4.2801 2.0483	2.2318	4.2801 4.2801	3.5382 3.5382
Accumulation shares (No Trail)				
Group 1 Group 2	17.335 10.5173	- 6.8177	17.3350 17.3350	14.2575 14.2575
Z Accumulation shares Group 1 Group 2	7.7806 4.1685	- 3.6121	7.7806 7.7806	6.3854 6.3854
Y Accumulation shares				
Group 1 Group 2	5.4635 2.3518	- 3.1117	5.4635 5.4635	4.4815 4.4815
Income shares Group 1	2.8209 1.7208	- 1.1001	2.8209 2.8209	2.4120
Group 2 Income shares (No Trail)	1.7208	1.1001	2.0209	2.4120
Group 1 Group 2	11.4269 6.5341	- 4.8928	11.4269 11.4269	9.7203 9.7203
Z Income shares Group 1 Group 2	6.2857 3.3278	- 2.9579	6.2857 6.2857	5.3344 5.3344
Y Income shares Group 1 Group 2	4.5692 1.9251	- 2.6441	4.5692 4.5692	3.8764 3.8764

Group 1: shares purchased prior to 1 April 2019 Group 2: shares purchased on or after 1 April 2019

Distribution tables

Distribution tables continued for the year 1 April 2019 to 31 March 2020

Distribution payable 31 May 2020	Net revenue pence per share	Equalisation pence per share	Net distribution payable 31.5.20 pence per share	Net distribution paid 31.5.19 pence per share
Accumulation shares				
Group 1 Group 2	2.7775 1.2425	1.5350	2.7775 2.7775	2.6751 2.6751
Accumulation shares (No Trail)				
Group 1 Group 2	11.2813 0.6941	- 10.5872	11.2813 11.2813	10.7958 10.7958
Z Accumulation shares				
Group 1 Group 2	5.0688 1.1992	- 3.8696	5.0688 5.0688	4.8419 4.8419
Y Accumulation shares				
Group 1 Group 2	3.5602 1.7952	- 1.7650	3.5602 3.5602	3.3991 3.3991
Income shares				
Group 1 Group 2	1.7848 0.2112	- 1.5736	1.7848 1.7848	1.7911 1.7911
Income shares (No Trail)				
Group 1 Group 2	7.2480 4.4816	- 2.7664	7.2480 7.2480	7.2273 7.2273
Z Income shares				
Group 1 Group 2	3.9926 0.9975	- 2.9951	3.9926 3.9926	3.9726 3.9726
Y Income shares Group 1 Group 2	2.9031 1.4438	- 1.4593	2.9031 2.9031	2.8870 2.8870

Group 1: shares purchased prior to 1 October 2019 Group 2: shares purchased on or after 1 October 2019

Equalisation applies only to shares purchased during the distribution period (Group 2). It is the average amount of revenue included in the purchase price of all Group 2 shares and is refunded to holders of these shares as a return of capital. Being capital it is not liable to income tax. Instead, it must be deducted from the cost of shares for capital gains purposes.

Regulatory statements

Statement of the Manager's Responsibilities in relation to the Financial Statements

The Collective Investment Schemes sourcebook ("COLL") requires the Manager to prepare financial statements for each annual accounting period which give a true and fair view of the financial position of the Company as at the end of the year and of the net revenue or expense and the net capital gains or losses on the scheme property of the Company for the year then ended. In preparing the financial statements the Manager is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in operation for the foreseeable future;
- comply with the disclosure requirements of the Statement of Recommended Practice relating to Financial Statements of Authorised Funds;
- follow applicable accounting standards; and
- keep proper accounting records which enable it to demonstrate that the accounts as prepared comply with the above requirements.

The Manager is responsible for the management of the Company in accordance with the Prospectus and the OEIC Regulations.

The Manager is responsible for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of the Depositary's Responsibilities in relation to the Financial Statements

The Depositary is responsible for the safekeeping of all of the property of the Company (other than tangible moveable property) which is entrusted to it.

It is the duty of the Depositary to take reasonable care to ensure that the Company is managed in accordance with the COLL, the Open-Ended Investment Companies Regulations 2001 (SI 2001/1228) ("the OEIC Regulations") and the Company's Instrument of Incorporation in relation to the pricing of, and dealings in, the shares of the Company, the application of the revenue of the Company, and the investment and borrowing powers of the Company.

Depositary's Report to Shareholders

Having carried out such procedures as we considered necessary to discharge our responsibilities and duties as Depositary of the Company, it is our opinion, based on the information available to us and the explanations provided, that in all material respects the Company, acting through the Manager:

- (i) has carried out the issue, sale, redemption and cancellation of shares in the Company, the calculation of the price of the Company's shares and the application of the Company's revenue in accordance with the COLL and, where applicable, the OEIC Regulations and the Instrument of Incorporation of the Company; and
- (ii) has observed the investment and borrowing powers and restrictions applicable to the Company.

Citibank Europe plc, UK Branch

London 28 September 2020

Independent auditors' report to the Shareholders of Invesco UK 2 Investment Series

Report on the audit of the financial statements

Opinior

In our opinion, the financial statements of Invesco UK 2 Investment Series (the "Company"):

- give a true and fair view of the financial position of the Company and each of the sub-funds as at 31 March 2020 and of the net revenue and the net capital losses on the scheme property of the Company and each of the sub-funds for the year then ended; and
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law), the Statement of Recommended Practice for UK Authorised Funds, the Collective Investment Schemes sourcebook and the Instrument of Incorporation.

Invesco UK 2 Investment Series is an Open Ended Investment Company ('OEIC') with three sub-funds. The financial statements of the company comprise the financial statements of each of the sub-funds. We have audited the financial statements, included within the Annual Report including Long Form Financial Statements (the "Annual Report"), which comprise: the balance sheets as at 31 March 2020; the statements of total return and the statements of changes in net assets attributable to shareholders for the year then ended; the distribution tables; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Emphasis of matter

In forming our opinion on the financial statements, which is not modified, we draw attention to note 1(a) to the financial statements which describes the Authorised Corporate Director's reasons why the financial statements of the Invesco UK Strategic Income Fund (UK) have been prepared on a basis other than going concern.

Conclusions relating to going concern

With the exception of the circumstances described in the Emphasis of matter paragraph above regarding the sub-fund Invesco UK Strategic Income Fund (UK), we have nothing to report in respect of the following matters in relation to which ISAs (UK) require us to report to you where:

- the Authorised Corporate Director's use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the Authorised Corporate Director has not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's or any of the subfunds' ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company's or any of the sub-funds' ability to continue as a going concern.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The Authorised Corporate Director is responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

Authorised Corporate Director's Report

In our opinion, the information given in the Authorised Corporate Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Independent auditors' report to the Shareholders of Invesco UK 2 Investment Series continued

Responsibilities for the financial statements and the audit

Responsibilities of the Authorised Corporate Director for the financial statements

As explained more fully in the Statement of the Manager's Responsibilities in relation to the Financial Statements set out on page 75, the Authorised Corporate Director is responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The Authorised Corporate Director is also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Authorised Corporate Director is responsible for assessing the Company's and each of the sub-funds ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Authorised Corporate Director either intends to wind up or terminate the company or individual sub-fund, or has no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the Company's shareholders as a body in accordance with paragraph 4.5.12 of the Collective Investment Schemes sourcebook as required by paragraph 67(2) of the Open-Ended Investment Companies Regulations 2001 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Opinion on matter required by the Collective Investment Schemes sourcebook

In our opinion, we have obtained all the information and explanations we consider necessary for the purposes of the audit.

Collective Investment Schemes sourcebook exception reporting

Under the Collective Investment Schemes sourcebook we are also required to report to you if, in our opinion:

- proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records.

We have no exceptions to report arising from this responsibility.

PricewaterhouseCoopers LLP

Chartered Accountants and Statutory Auditors Edinburgh 28 September 2020

General Information

Directors of the Manager

Rachel Court*
Judith Eden*
Matthieu Grosclaude***
Rene Marston**
Hayley Norford
Graeme Proudfoot (ceased to be a Director 30 June 2019)
Andrew Schlossberg (ceased to be a Director 13 May 2019)
Douglas Sharp
Alan Trotter

- * Effective 11 September 2019 Rachel Court and Judith Eden were appointed as Independent Non-Executive Directors of Invesco Fund Managers Limited.
- ** Effective 8 January 2020 Rene Marston was appointed as a Director of Invesco Fund Managers Limited.
- *** Effective 9 January 2020 Matthieu Grosclaude was appointed as a Director of Invesco Fund Managers Limited.

Authorised Corporate Director (the "Manager")

Invesco Fund Managers Limited

Registered Office: Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK Registered in England No. 898166

The Manager's investment adviser is:

Invesco Asset Management Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK

Registered in England No. 949417

Invesco Asset Management Limited and Invesco Fund Managers Limited are authorised and regulated by the Financial Conduct Authority.

Registrar

Invesco Fund Managers Limited

Registered Office: Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK

For registration enquiries please call free on telephone 0800 085 8677 or write to us at: Invesco Administration Centre, PO Box 11150, Chelmsford CM99 2DL, UK

Depositary

Citibank Europe plc, UK Branch

Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, UK

Authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority.

Independent Auditors

PricewaterhouseCoopers LLP

Atria One, 144 Morrison Street, Edinburgh, EH3 8EX

Further information

General enquiries

Client Services Team 0800 085 8677 International calls +44 (0)1491 417000

Lines are open 8.30am to 6pm, Monday to Friday, excluding UK Bank Holidays.

www.invesco.co.uk enquiry@invesco.com

Fax 01491 416000

Post:

Invesco Administration Centre, PO Box 11150, Chelmsford CM99 2DL, UK

All instructions for investment and other correspondence relating to your account should be sent to this address. If you do not use this address, instructions for investment will be returned to you and our response to other correspondence may be delayed.

To invest

ICVC Dealing Line 0800 085 8571*

* The initial investment into an ICVC account must be made by completing and signing an application form; subsequent investments into the account can be made by post or via the telephone dealing line.

Clients must confirm that they have been provided with the most up to date relevant Fund and share class specific Key Information Document(s) prior to investing.

Telephone conversations of all dealers, staff and those of clients on our Dealing Lines will be recorded for mutual protection.

Valuations

Automated Valuation Service 0800 028 4050. Lines are open 24 hours a day.

Online Valuation Service. Available to UK residents and their financial advisers only. To register for this service please go to www.invesco.co.uk

Further information on our products, including the most up to date relevant Fund and share class specific Key Information Document(s) and the Supplementary Information Document, is available using the contact details as set out in the section "General Enquiries" above.

The Prospectus, which contains a written statement of the terms and conditions of the Company, can be obtained from the Manager, as can copies of Interim and Annual Reports. Please call our Client Services Team Line on 0800 085 8677 or log onto our website (www.invesco.co.uk).

Telephone conversations of all staff and those of clients may be recorded for mutual protection.

Issued by Invesco Fund Managers Limited

Invesco Fund Managers Limited is authorised and regulated by the Financial Conduct Authority FCA Registered No. 119298

Registered in England No. 898166

Registered address: Perpetual Park, Perpetual Park Drive, Henley-on-Thames,

Oxfordshire RG9 1HH, UK